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Abstract 
Breast cancer is a heterogeneous group of diseases where metastatic spread is the major 
cause of death. Surveillance of treatment response and tumour burden is currently 
achieved with periodic medical imaging over the course of the disease. Circulating 
tumour DNA (ctDNA) is a blood-based biomarker where short fragments of DNA are 
released from the tumour into the blood circulation. These fragments contain identical 
somatic mutations from the tumour and can be acquired through a routine blood draw 
for further analysis such as variant detection (Next Generation Sequencing) and 
quantification (Droplet Digital PCR). Routine analysis of ctDNA provides a means of 
monitoring tumour burden, measuring treatment response and surveillance of metastatic 
spread. Despite previously successful ctDNA analytical studies, its adoption into 
clinical diagnostics is hindered by a lack of standardised operating protocols. This 
thesis aimed to 1) contribute to the development of a ctDNA analytical pipeline for 
New Zealand and,  2) demonstrate ctDNA sensitivity for the surveillance of metastatic 
breast cancer.   
 
The first objective was accomplished by comparing two commercially available cfDNA 
blood collection tubes. Differences in sample stabilisation by the prevention of gDNA 
contamination from WBC lysis was measured for both tubes over a period of 14 days. 
No statistically significant results were observed between the two tubes, hence 
consideration of price and product availability were considered for choosing a tube for 
clinical sample collection.  
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Optimisation of mutation identification and quantification techniques were carried out 
using a commercial cfDNA reference standard set. The standards were used in targeted 
NGS to determine mean target coverage and number of variants detected for various 
DNA input amounts (20 ng, 5 ng and 1ng) at a low mutant allele frequency (1%). It 
was observed that the 20 ng sample achieved the highest mean target coverage and thus 
the highest number of somatic variants detected. The standards were also used to 
optimise in-house ddPCR assay design for two variants (NRAS Q61K and PIK3CA 
E545K). The detection sensitivity of each assay was determined to identify the mutant 
variants at three allele frequencies within a background of 10, 000 wild type copies. 
Detection sensitivities of 0.03% and 0.49% were observed for the NRAS and PIK3CA 
assays, respectively.  
 
To achieve the second objective, the ctDNA methodology was applied to a small pilot 
study of six metastatic breast cancer patients to determine response to treatment and 
monitor tumour burden in comparison to current clinical practices. A significant 
reduction in ctDNA levels was observed in three patients within two chemotherapy 
cycles, potentially indicating a positive response to treatment. However, ctDNA 
analysis for the remaining three patients was inconclusive. 
The findings of this study contribute to the development of a standardised ctDNA 
analytical protocol and demonstrate its utility for surveillance of metastatic breast 
cancer patients. Although further research in this area is yet to be done, the adoption of 
ctDNA analysis for the surveillance of cancer within New Zealand will contribute to a 
shift in cancer care towards primary services and help achieve the New Zealand 
Primary Health Care strategy “Better, Sooner, More Convenient”.
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Chapter 1  
Introduction 
 
1.1  Breast Cancer  
Cancer is caused by genetic alterations and aberration within an individual’s genome 
(Hanahan and Weinberg, 2000). These genetic changes result in the deregulation of 
normal cellular functions that drive neoplastic development (Fig 1.1) (Hanahan and 
Weinberg, 2011).  
Figure 1.1 Hallmarks of cancer. The original six hallmarks of cancer (Hanahan and 
Weinberg, 2000) along with the four new ones as proposed by Hanahan and Weinberg, 2011. 
(Figure reproduced from Cell, 100, pg 646-674, Hanahan and Weinberg, 2011 with permission 
from Elsiever). 
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Breast cancer is widely regarded as a collective group of disease due to its 
heterogeneous nature (Turashvili and Brogi, 2017). Abnormal growth and proliferation 
of such cancers typically occurs within the breast cells lining the ducts (pathway for the 
expulsion of milk) and lobules (glands where the milk is produced) (Gedes, 2007; 
American Cancer Society, 2017). The histological classification of breast cancer 
broadly divides all cases into either In Situ (localised within the cellular basement 
membrane) or invasive (spread beyond the cellular basement membrane) carcinomas 
(Fig 1.2).  
 
  
Figure 1.2 Schematic representation of where cancers arise in the female breast. Breasts 
consist of a network of lobules and ducts. A) In Situ cancers are contained within the 
basement membrane. B) Invasive cancer spreads beyond the basement membrane to 
surrounding structures. (Figure adapted from Cancer Research UK, (2018), Ductal 
Carcinomas In Situ ) 
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Further sub-classification of In Situ carcinomas include Ductal Carcinoma In Situ 
(DCIS) and Lobular Carcinoma In Situ (LCIS). Likewise, invasive carcinomas can be 
further histologically sub-classified as invasive lobular, ductal, mucinous, papillary, 
tubular, infiltrating ductal and medullary (Malhotra et al., 2010). Metastatic disease 
occurs in advanced breast cancer cases (stage 4) and involves the progression of cancer 
into regional and distant sites (Weigelt, Peterse and van't Veer, 2005). Common sites of 
breast metastatic disease include the brain, bones, lungs and the liver; of these sites 
bony disease is most prevalent and occurs in 70% of metastatic cases (Akhtari et al., 
2008; Kennecke et al., 2010). 
 
1.1.1 Incidence Worldwide 
Breast cancer is the leading cause of death in female cancer patients, causing 571,000 
deaths worldwide in 2015 (World Health Organization, 2017). New breast cancer cases 
make up 11.9% of total cases in both developed and developing nations on a yearly 
basis (Ferlay et al., 2015). Amongst developed nations, North America, Europe and 
Australasia have the highest incidence rates (Fig 1.3) which is attributed to elevated risk 
factors such as family history, early onset for menstruation, late age for first pregnancy, 
obesity, excessive alcohol intake, prolonged use of oral contraceptives and post-
menopausal hormone replacement therapy (Parkin et al., 2004; Weir, Day and Ali, 
2007). Disparities due to socio-economic status plays a major role in the mortality and 
incidence rate of breast cancer. A higher incidence rate is typically observed in  women 
of an upper socio-economic class compared to lower-socio-economic class. However, a 
higher mortality rate is prevalent in the latter group of women and in developing 
countries, possibly because of lower uptake or availability of breast cancer screening 
services (Tao et al., 2014). Nevertheless, factors such as younger start age for child-
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bearing and prolonged continuous breast-feeding (both common practices in third-
world countries and low-socio-economic individuals) are protective against breast 
cancer and are potentially a further explanation for the low incidence in some sub-
populations (Parkin et al., 2004.) 
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1.1.2 Breast Cancer in New Zealand  
Breast cancer is the third most common cancer in New Zealand (Ministry of Health, 
2017) with 3000 new diagnoses and 600 associated deaths every year (Breast Cancer 
Foundation NZ, 2017). With a population of ~4.7 million individuals, the rate of new 
cases is continually increasing due to New Zealand's aging population and the 
implementation of a government funded screening program (Seneviratne  et al., 2016a). 
Māori (who make up 15% of the total population) and Pacific Island (who make up 7% 
of the total population) ethnic groups have a significantly higher incidence rate 
compared to other ethnicities. They also tend to have breast cancer with a significantly 
lower 5-year survival rate and an overall higher mortality rate compared to New 
Zealand Europeans (Jeffreys et al., 2005; Sarfati et al., 2006). Cohort studies looking at 
the disparity of breast cancer mortality between Māori and non-Māori, show Māori tend 
to present for care at a more advanced stage of disease and are more likely to 
experience a prolonged waiting time for treatment (Dachs et al., 2008; Seneviratne et 
al., 2015a). Lawrenson et al., (2016b) looked at characteristics of urban and rural 
differences in New Zealand breast cancer patients and found that a significant number 
of rural patients were older and of Māori descent. Subsequently rural Māori women 
were less likely to have undergone mammography screening in comparison to urban 
Māori patients and thus were 2.5 times more likely to present with advanced metastatic 
disease. Differences in health care access has been reported as a significant reason for 
observed ethnic and social economic differences with regard to final breast cancer 
outcome for Māori and non-Māori (Senevirathne et al., 2015b). Senevirathne and 
colleagues (2015b) indicate factors such as costs, geographical distance from treatment 
facility, availability of transport and social support as barriers to accessing specialist 
health care services. Thus a “lack of co-ordinated care” for indigenous Māori is a key 
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factor for poorer treatment outcomes  (Robson and Ellison-Loschmann 2016). A 
community-based approach for cancer care via primary health care and Māori providers 
has been indicated as a significant requirement for better treatment outcomes for cancer 
patients in New Zealand (Robson and Ellison-Loschmann 2016). 
 
1.1.3 Clinical Practices for Diagnosis and Surveillance of Breast Cancer 
Breast cancer screening has significantly decreased the mortality rate amongst women 
in the last thirty years (Ministry of Health, 2009). The New Zealand clinical practice 
involves utilising the triple assessment for breast cancer diagnosis which includes 
clinical examination, mammogram/ultrasound and cytological and tissue diagnosis 
which has a sensitivity and specificity greater than 90% (Collins and Simpson, 1997). 
Mammograms are the first assessment of diagnosis and the New Zealand government 
has a fully funded screening program BreastScreen Aotearoa, which provides biannual 
mammogram screening for women between the ages of 45-69. Further procedures such 
as Fine Needle Aspiration (FNA) and core biopsy may be required for tissue sampling 
for molecular investigation and identification of specific markers such as Estrogen 
Receptor (ER), Progesterone Receptor (PR) and Human Epidermal Growth Factor 2 
(HER2) which enable cancer subtyping and impact therapy selection (Ministry of 
Health, 2013).  
 
While breast cancer typically occurs in post-menopausal women (> 45 years), a small 
proportion is made up of young women (< 35 years, 6% of all cases) and men (20 
individuals diagnosed every year) (Breast Cancer Foundation NZ, 2017). Female 
patients below 35 years of age who are diagnosed with breast cancer tend to present a 
more aggressive state of disease with increased rates of metastatic spread. Potential 
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breast cancer patients of this age group currently do not meet the criteria for the free 
screening program and a diagnosis usually only occurs after a visible lump is felt. In 
such cases the cancer may already be in an advanced and aggressive state, thereby 
limiting treatment options. 
 
Surveillance of advanced and metastatic disease progression typically involves imaging 
techniques and procedures such as ultrasound, Magnetic Resonance Imaging (MRI), 
Computed Tomography (CT) and Positron Emission Tomography (PET) scans over the 
patient’s course of treatment (Andreea et al., 2011). Of these, CT and MRI scans are the 
most commonly used in metastatic cases as they provide a means of “response 
assessment” by measuring dimension of the metastatic lesions (Therasse et al., 2000). 
While both procedures have sensitivities greater than 90%, disadvantages include high 
operative costs, increased radiation exposure, and potential risk of false positive 
diagnosis (Yoon et al., 2009). Furthermore, the number of and subsequent time between 
imaging procedures is dependent on each patient’s cancer stage, current treatment 
regime and availability of imaging services. As such, significant lags between 
surveillance can potentially be detrimental to the patient in terms of treatment 
outcome/response and further metastatic dissemination.  
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1.1.4 Molecular Subtypes  
Immunohistochemistry and gene expression profiling have sub-classified breast cancer 
into four well established molecular classes: luminal A, luminal B, HER2 enriched 
(positive) and Basal-like (Polyak, 2011; Guiu et al., 2012). A further subtype known as 
Normal-like has since been identified, however its molecular characteristics are not yet 
well understood (Peddi et al., 2012). 
  
Luminal A is the most common breast cancer subtype and makes up  approximately 50-
60% of all diagnosed cases. LCIS and many infiltrating lobular carcinomas cases fall 
under this sub-type (Eroles et al., 2012). Immunohistochemistry defines luminal A 
tumours as generally hormone receptor positive but lacking in HER2 (ER+, PR+, 
HER2-). These tumours typically show low levels of the proliferation marker protein 
KI-67 and thus most patients have longer survival and lower relapse rates (Yersal and 
Barutca, 2014). Patients with luminal A tumours also respond better to hormonal 
treatment compared to conventional chemotherapy (Dai et al., 2015).  
 
Luminal B tumours are similar to luminal A in their classification. They are typically 
positive for both hormone receptors and HER2 (ER+, PR+, HER2+), although a small 
proportion are both ER- and HER- (Dai et al., 2015). These tumours tend to be a higher 
grade and thus have a significantly worse prognosis due to their aggressive phenotype 
(Eroles et al., 2012). Hormonal therapy typically doesn't have much effect on these 
tumour subtypes whereas neoadjuvant chemotherapy has been shown to be more 
effective (Yersal and Barutca, 2014).  
HER2 enriched breast cancer is due to the amplification of the ERBB2 gene resulting in 
over-expression of the HER2 protein (Prat, Pascual, and Adamo, 2017). Typically, 
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HER2 enriched breast cancer patients present the ER-, PR-, HER2+ characteristics, 
however a proportion (30%) have also been identified as hormone receptor positive 
(Llombart-Cussac et al., 2017). Furthermore, overexpression in HER2 corresponds to 
overexpression in other cancer related genes, namely Tumour Protein 53 (TP53). 
Mutations within this tumour suppressor gene typically cause patients to have a poor 
clinical prognosis due to its loss of protective function during tumorigenesis (Eroles et 
al., 2012; Dai et al., 2015). 
 
Basal-like tumours generally lack both receptors and HER2 amplification ( ER-, PR- 
and HER-) and are sometimes known as Triple Negative Breast Cancer (TNBC). Both 
Basel-like and TNBC sub-types share immunohistochemistry similarities, however, 
distinct gene expression profile results in further subclasses: triple-negative-basal-like, 
triple-negative non-basal-like, basal-like-triple-negative and basal-like-non-triple-
negative (Prat et al., 2013). All constitute a very aggressive form of breast cancer for 
which there is currently no standard therapy available. Furthermore,  individuals 
diagnosed with such subtypes tend to have a very poor prognosis and early onset of 
metastatic disease (Dai et al., 2015).  
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1.1.5 Biomarkers  
Biological markers or “biomarkers” indicate a response or state which is either 
physiological, pathological or pharmacological in nature. In cancer patients, biomarkers 
have been previously used as either diagnostic, prognostic or predictive tools to 
measure cancer (Idowu et al., 2015). Breast cancer specific biomarkers include the 
immunohistochemistry analysis for the presence of hormone receptors ER and PR and 
over-expression of the HER2+ protein (Weigel and Dowsett, 2010). Previous studies 
have also identified antigen KI-67 as prognostic and predictive marker of treatment 
response as it provides a measure of cellular proliferation (Denkert et al., 2015).   
 
Blood based biomarkers are of special interest due to their acquisition via a minimally 
invasive blood draw. Current blood-based biomarkers used in other cancers include the 
Prostate Specific Antigen (PSA) and Carcinoembryonic Antigen (CEA). However, both 
these markers have low sensitivity and specificity due to their elevated levels in 
asymptomatic individuals (Holdenrieder et al., 2016). Hence, there is a need for a blood 
based cancer-specific biomarker that can provide a highly sensitive measure for 
diagnosis and surveillance.  
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1.2 Circulating Tumour DNA  
Circulating tumour DNA (ctDNA) is a blood-based biomarker consisting of short 
fragments of extracellular DNA that are released from tumours into the blood 
circulatory system. These short fragments contain somatic mutations from the primary 
tumour or metastatic lesions and provide a minimally invasive means for characterising 
tumour dynamics such as growth and dissemination (Cheng, Su and Qian, 2016). The 
initial discovery of the presence of nucleic acids in the blood circulation was made by  
Mendal and Metais (1948). Their findings showed  individuals of various physiological 
and pathological states had elevated levels of circulating DNA in comparison to healthy 
controls. The concept of free-floating DNA within the blood circulation did not come 
into scientific light till 1966, when Tan et al. (1966) demonstrated the detection of 
double stranded DNA (dsDNA) using antibodies in the sera of Systemic Lupus 
Erythematosus (SLE) patients. Tan and his colleagues (1966) acknowledged the origin 
of this DNA was unknown but hypothesised that it must be of an "endogenous origin" 
due to its appearance in various other diseases as previously observed by Mendal and 
Metais (1948).  
 
The design and implementation of a radioimmunoassay by Leon et al. (1977) showed a 
distinct correlation between ‘circulating DNA’ and cancer due to the significant 
increase in nucleic acid concentration observed in cancer patients’ plasma. Further 
findings showed patients with metastatic disease had significantly higher circulating 
DNA levels compared to non-metastatic patients (Leon et al., 1977). These findings 
were the first to illustrate the potential use of circulating DNA as a surveillance 
mechanism for advanced stage cancer patients and ultimately laid the foundation for 
future studies in  the development of ctDNA analysis.  
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Later studies showed the origin of circulating DNA correlated with the presence of a 
tumour.  (Stroun et al. 1989). Stroun and colleagues carried out an in vitro DNA 
synthesis test using plasma DNA extracted from cancer patients and healthy controls. 
Their findings indicated significant amounts of “neoplastic DNA” within the plasma 
sample of the cancer patients. By the late 1980s, it was well established that oncogenic 
mutations play a significant role in the development of many tumour types (Bos, 1989; 
Barbacid, 1990). The presence of such driver mutations detectable within the plasma of 
cancer patients was first demonstrated by Anker et al. (1997). KRAS point mutations 
were identified by Anker and colleagues (1997) in the plasma DNA of colorectal 
adenocarcinoma patients. These somatic mutations were identical to those present in the 
tumour itself, indicating the potential of variant characterisation within the  primary 
tumour using circulating  plasma DNA.  
 
Collectively, these significant historical findings provide a solid foundation for the 
further development of ctDNA as a potential clinical diagnostic and surveillance tool. 
However, further developments of ctDNA’s biological characteristics and analytics are 
required to enhance our understanding of the biomarker’s robustness and future clinical 
utility. A time-line showing all relevant studies highlights technical developments that 
bring the clinical use of ctDNA closer every year (Fig 1.4).
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1.2.1 Biology and Molecular Characteristics of ctDNA  
While there is still a significant lack of knowledge regarding the biological 
characteristics of ctDNA, several studies have made advances in relation to ctDNA 
fragment size, mechanism of release and circulatory half-life (Thierry et al., 2016). It is 
thought that all cells contribute to the pool of cell free DNA (cfDNA) via three cellular 
mechanisms: apoptosis, necrosis and active secretion. The difference between cancer 
patients and healthy individuals is that in cancer patients, tumour DNA is also released 
(Bronkhorst et al., 2016). 
 
1.2.1.1 Mechanisms of cellular circulating DNA release 
Early studies hypothesised that Circulating Tumour Cells (CTC) were responsible for 
the subsequent release of ctDNA into the circulation (Stroun et al., 2000). Sorenson et 
al. (1997), carried out a study where the number of cancer cells in relation to cellular 
free plasma DNA in pancreatic cancer patients was calculated. In order to produce the 
amount of tumour DNA found in the plasma of a series of patient samples, Sorenson 
showed that the number of circulating tumour cells would have to exceed 1000 cancer 
cells/ mL of plasma, a feat difficult even for the most advanced cancer cases.  
 
Further studies have shown that cellular death processes such as apoptosis and necrosis 
of the primary tumour mass were more likely to contribute to the subsequent release of 
DNA into the blood (Crowley et al., 2013) (Fig 1.5). A study by Jahr et al. (2001), 
identified that the majority of plasma DNA fragments extracted from the plasma of 
cancer patients were of a size similar to the apoptosis’s ladder-like degradation pattern 
as observed by Nagata (2000). Observations of Jahr and colleagues (2001) indicate that 
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the presence of long DNA fragments (>1000bp) were likely due to necrosis, similar to 
that previously observed by Anker et al. (1999). The study by Anker and colleagues 
(1999) suggest that necrosis plays a role in releasing a large amount of DNA into the 
circulation of patients with advanced stage cancer or metastatic disease. A further 
alternative pathway suggested for the release of tumour DNA into the circulation is 
active secretion (Stroun et al., 2001; Abolhassani, Tillotson and Chiao, 1994). Several 
studies have utilised in vitro cell culture models to demonstrate the plausibility of this 
phenomenon. Bronkhorst et al. (2016) carried out such a study and identified the 
previously reported DNA fragment of 160 bp pattern associated with apoptosis. In 
addition, DNA fragments of 2000 bp in length were also identified, which Bronkhorst 
and colleagues (2016) attribute to its release via a protein complex. Other studies also 
suggest that active secretion of circulating DNA acts as a molecular message system 
and plays a role in the development of metastatic disease at distant sites (García-Olmo 
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Figure 1.5 Mechanism of circulating tumour DNA into the blood stream. Apoptosis of both 
healthy and tumour cells are shown as the major contributor of extracellular DNA. Although active 
cellular  secretion is also an acknowledged source (not shown). The healthy derivative cfDNA is also 
released via apoptosis (Figure reproduced from Nature Reviews Clinical Oncology 10, 472-484,  
Crowley et al., 2013 with permission from Springer Nature). 
 
 
Figure 0.6 Mechanism of circulating tumour DNA into the blood stream. Apoptosis of both 
healthy and tumour cells are shown as the major contributor of extracellular DNA. Although active 
cellular secretion is also an acknowledged source (not shown). (Figure adapted from Crowley et al., 
2013). 
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1.2.1.2 Fragment Size 
Circulating tumour DNA consists of short DNA fragments less than 200 bp in length. 
Jahr et al. (2001) was one of the first to publish the size profile of circulating plasma 
DNA in cancer patients and quantify the length of ~180bp. However, later studies have 
since indicated that the majority of the fragments are in fact between 161bp and 170 bp 
(Suzuki et al., 2008; Jiang et al., 2015). A recent study by Underhill et al. (2016) 
showed that the majority of fragments within this range were cfDNA, and that ctDNA 
could consist of even shorter fragments between 132 bp and 145 bp (Fig 1.6). Underhill 
et al. (2016) compared the size profile of ctDNA in a melanoma patient and healthy 
controls. The melanoma patient had shorter DNA fragments with the BRAF V600E 
variant present, in comparison to the healthy controls had slightly longer fragments. 
While this phenomenon has been previously observed in cell free foetal DNA cases its 







Figure 1.6 Fragment size of cfDNA from healthy controls in relation to ctDNA from a 
melanoma patient. Size profiling was carried out by deep sequencing. cfDNA (purple ) 
has an average peak of 165 bp while ctDNA (green) has an lower average peak of only 
145 bp (Figure reproduced from PLOS Genetics 12, e1006162, Underhill et al., 2016 with 
permission from PLOS Genetics).  
 
 
Figure 0.7 Fragment size of cfDNA from healthy controls in relation to ctDNA from a 
melanoma patient. Size profiling was carried out by deep sequencing. (Figure adapted 
from Underhill et al., 2016).   
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1.2.1.3 Circulatory Half-life 
To address the question of cfDNA clearance from the circulatory system, Lo et al. 
(1999) investigated the clearance rate of cell free foetal DNA from the mother's 
circulation postpartum. Their findings indicate that circulating foetal DNA has a half-
life of ~16.3 minutes and was typically cleared from the circulation within 1 hour of 
giving birth. In a further study, To et al. (2003) described the clearance of the Epstein-
Barr Virus (EBV) DNA within the circulation of patients diagnosed with 
Nasopharyngeal Carcinoma (NPC). Their findings showed an average half-life of EBV 
DNA was 139 minutes post-surgical removal of the tumour. Further analysis within a 
follow-up period, showed that 73% of patients had no detectable EBV DNA. However, 
patients with increasing amounts of EBV DNA eventually developed clinical relapse. 
Thus, incomplete removal of the circulating viral DNA may be indicative of 
progressive disease status. 
 
1.2.2 Clinical Application 
The clinical utility of ctDNA as a diagnostic and surveillance tool has the potential to 
ultimately change the way cancer is managed here in New Zealand. Specific areas 
where ctDNA analysis is potentially advantageous over current methods include 
measuring tumour burden, predicting patient prognosis, identifying therapeutic targets 
and monitoring response and/or resistance to treatment (Alix-Panabières and Pantel, 
2016).  
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Dawson et al. (2013) compared tumour surveillance using conventional CT scans and 
ctDNA analytics in 30 metastatic breast cancer patients. The ctDNA versus CT scan 
results for one metastatic patient are shown in Fig 1.7. Dawson and colleagues (2013) 
showed that several variants within the plasma ctDNA had a similar trend of response, 
where ctDNA levels decreased initially within the first 150 days of treatment. After this 
period the ctDNA concentrations increased, despite CT scans indicating stable disease. 
Quantification of ctDNA levels showed that the cancer was developing resistance to the 
drug Epirubicin during the period where metastatic disease appeared stable by CT 
imaging. ctDNA analysis also identified progressive disease much earlier than the 
Figure 1.7 ctDNA analysis versus CT scans in a metastatic breast cancer patient. Several 
mutations were quantified over the patients course of treatment. The general trend showed a 
decrease in ctDNA levels within the initial 150 days of treatment. After this point, the levels 
of ctDNA increased significantly, despite CT scans indicating stable disease. Progressive 
disease was diagnosed by ~450 days post initial treatment. The patient was subsequently 
switched to a different cytotoxic drug, however this only had a marginal affect before ctDNA 
levels started to increase rapidly again. The patient then passed at ~700 days (Figure 




Figure 0.8 ctDNA analysis versus CT scans in a metastatic breast cancer patient. Several 
mutations were quantified over the patients course of treatment. The general trend showed a 
decrease in ctDNA levels within the initial 150 days of treatment. After this point, the levels 
of ctDNA increased significantly, despite CT scans indicating stable disease. Progressive 
disease was diagnosed by ~450 days post initial treatment. The patient was subsequently 
switched to a different cytotoxic drug, however this only had a marginal affect before ctDNA 
levels started to increase rapidly again. (Figure adapted from Dawson et al., 2013) 
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routine radiological scans (Dawson et al., 2013). Due to the heterogeneous nature of 
breast cancer, ctDNA provides a means of characterising the genetic make-up of the 
primary tumour through the presence of specific somatic mutations within plasma 
samples (Wang et al., 2017). A study conducted by The Cancer Genome Atlas Network 
(TCGA), showed the most common genes mutated across 825 breast cancer patients 
include PIK3CA, TP53, CDH1 (Koboldt et al., 2012). TCGA also found that many of 
these mutations were characteristic of the four major breast-cancer subtypes and that 
heterogeneity occurred within each subtype rather than across subtypes (Koboldt et al., 
2012). This phenomenon was also observed in a clinical case study by Murtaza et al. 
(2015), in which the ctDNA from a ER+ and HER2+ metastatic breast cancer patient 
undergoing treatment was analysed over 3 years. Murtaza and colleagues (2015) 
observed the evolution of clonal mutations where the “fittest” neoplastic cells arise 
from tumour environmental selection pressure and are associated with the variable 
treatment response of the metastatic lesions (Greaves and Maley, 2012). 
 
Other studies have demonstrated the feasibility of developing specific somatic 
mutations for use as treatment response biomarkers. Mutations within the PIK3CA gene 
are highly prevalent in breast cancer cases. Higgins et al. (2012) evaluated the potential 
of detecting such mutations via ctDNA analysis of serially obtained plasma samples. 
Higgens et al. (2012) showed patients PIK3CA mutational status can change during 
disease progression. Routine evaluation of the presence of these mutations will provide 
valuable clinical information regarding clonal evolution and response to treatment and 
tumour burden. 
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Findings from ctDNA clinical studies such as Higgens et al. (2012) and Dawson et al. 
(2013) clearly show the benefits of ctDNA analysis in breast cancer patients (De 
Mattos-Arrudaabc and Caldasade, 2016). However, use of ctDNA is still far from being 
integrated into routine cancer management due to a lack of standardised protocol for its 
analysis and quantification (Spindler, 2017). The clinical application of ctDNA as a 
surveillance tool will have profound benefits for the management of breast cancer for 
New Zealand patients. Its minimally invasive nature allows acquisition of sample 
collection to occur in a primary health care setting such as a local GP’s office or health 
care centre. The clinical use of ctDNA also has potential to especially benefit cancer 
patients from rural areas and individuals whose cultural beliefs discourage them from 
seeking specialist care. As previously stated, Māori and Pacifica breast cancer patients 
are significantly disadvantaged in terms of final cancer outcome largely due to social 
and ethnic inequalities (Senevirathne et al., 2016b). Developing ctDNA analysis for 
primary health care services will aid in reducing the effect of such inequalities and 
improve the community-based care available for all New Zealanders.  
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1.2.3 Developing a Standardised Protocol for ctDNA Analysis in New Zealand 
Many international studies have successfully carried out ctDNA analysis, however there 
is a lack of consensus regarding a standardised protocol (Devonshire et al., 2014). A 
general workflow of the ctDNA methodology is presented in Fig 1.8, which highlights 
several variables that need further validation. 
1.2.3.1  Sample Collection  
A significant advantage of ctDNA analysis is its acquisition from a routine blood draw. 
This means that blood samples can be collected from patients located anywhere within 
New Zealand and the sample shipped to the processing laboratory. However pre-
analytic variables such as sample stability over a prolonged time and variable shipment 
conditions have potential adverse effects on biomarker integrity (El Messaoudi et al., 
2013). Development of a mechanism to protect samples against these variables is 
critical for broad ctDNA use as a clinical tool in New Zealand.  
 
The use of specialist cfDNA blood collection tubes are potentially a viable option for 
clinical sample collection. To test this, Norton et al., (2013a) compared standard 
K3EDTA collection tubes against Streck Cell-Free DNATM Blood Collection Tubes 
(BCT). The Streck tubes consist of a proprietary based preservation buffer designed to 
prevent White Blood Cell (WBC) lysis and subsequent genomic DNA contamination of 
the sample. As per the manufacturer’s guidelines, samples drawn into these tubes are 
stable under various shipment conditions and temperatures for up to 14 days post 
collection. Norton and colleagues (2013a), tested the manufacturer’s claims in their 
study and showed that the Streck tubes had a notable lack of genomic DNA 
contamination despite being subjected to conditions such as shaking and increasing 
storage temperature. Samples drawn into K3EDTA tubes however had a significant 
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increase in genomic DNA contamination after being subjected to identical conditions. 
In a further study, Norton et al. (2013b) compared genomic DNA contamination over a 
14 day period in samples drawn into both Streck and K3EDTA tubes. A marginal 
increase in genomic DNA (4.5 fold) was observed for the Streck tubes in contrast to 
samples drawn into K3EDTA tubes, which had a significant increase in genomic DNA 
(>200 fold). Several other researchers have also conducted similar studies (Diaz et al., 
2016; Kang et al., 2016 and Warton et al., 2017), and all acknowledge the Streck tubes 
as superior to standard K3EDTA tubes and hence recommended its subsequent use in 
downstream ctDNA analysis.  
 
Competitor manufacturers have also released cfDNA blood collection tubes.  Currently 
available and previously validated products include the Qiagen PAXgene Blood DNA 
Tube (Toro et al., 2015) and the CellSearch® CellSave preservation tubes (used for 
analysis of for circulating tumour cells) (Rothwall et al., 2016). Comparisons of such 
tubes against Streck and K3EDTA tubes have identified the significance of using a 
preservation buffer for sample stability (Warton et al., 2017).  The Streck tubes, 
however are regarded as the “Gold Standard” due to their prolonged period of sample 
stability (14 days) at various temperatures (6ºC-37ºC). Whether this observation holds 
firm in comparison to similar products recently released such as the Roche Cell Free 
DNA Collection Tubes® is yet to be determined.  
 
1.2.3.2 Sample Processing 
ctDNA is present only in the blood circulation of cancer patients in contrast to cfDNA 
which is present in all individuals. Plasma which contains both cfDNA and ctDNA in 
the case of cancer patients is the preferred substrate for ctDNA analysis rather than 
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serum. While previous studies have identified higher levels of cfDNA in patient serum 
samples, Lee et al., (2001) compared the initial concentration of cfDNA and the 
subsequent genomic DNA contamination in both plasma and serum samples of healthy 
volunteers. Results from their study, showed serum samples consisted of 20X more 
cfDNA than the plasma samples, however, genomic DNA contamination increased to 
over 1000X in serum samples within a four-day period. Lee and colleagues (2001) 
attributed this phenomenon to WBC lysis during the clotting procedure. Thus, 
monitoring a cancer patient’s ctDNA levels using serum samples may prove difficult 
due to ctDNA being heavily diluted with the large amount of genomic DNA present (El 
Messaoudi et al., 2013).  
 
Centrifugation of whole blood samples can also affect the yield and integrity of ctDNA 
in clinical patient samples where the plasma is removed from the red blood cells (RBC). 
A double centrifugation step has been shown to successfully reduce the amount of total 
circulating DNA background naturally present in samples during collection (Herrera et 
al., 2005) Using a slow centrifugation speed first followed by a second faster speed also 
reduces potential WBC lysis by centrifugation force (van Ginkel et al., 2017). 
Furthermore, the number of freeze-thaw cycles for plasma samples should be limited in 
order to prevent WBC lysis during sample thawing. El Messaoud et al. (2013) 
compared extracted total circulating DNA against the number of freeze-thaw cycles and 
identified that three cycles resulted in a significant decrease in total circulating DNA 
levels. Thus, samples should be aliquoted to prevent multiple freeze-thaw cycles prior 
to long term storage. 
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Methods for cfDNA extraction have progressed significantly since the first 
identification of nucleic acids present in the blood. Previous extraction methods 
involved THP Triton/Heat/Phenol (THP), salting out, magnetic beads and guanidium 
thiocyanate (Xue et al., 2009). However, the commercialisation of cfDNA extraction 
kits provides a robust method adaptable to both research and clinical settings. The 
Qiagen QIAmp Circulating Nucleic Acid (CNA) extraction kit, has been extensively 
used in various clinical studies which have shown to have high efficiency of cfDNA 
extraction compared to other products (Devonshire et al., 2014). A validation 
experiment comparing the recovery efficiency of a 564 bp reference standard spike-in 
(at various amounts) between the QIAmp® CNA kit, QIAamp® DNA Blood Mini kit 
and the NucleoSpin® Plasma XS kit. The CNA kit recovered 90-100% of the spike-in 
standard compared to 40-80% for the Blood Mini kit and 5-35% for the NucleoSpin kit 
(Page et al., 2013). Currently there is no specific protocol for the extraction of ctDNA 
by itself. Thus, specific techniques for somatic mutation identification and subsequent 
quantification are used for the analysis of ctDNA.  
 
1.2.3.3 Mutation Identification  
Next Generation Sequencing (NGS) is a highly efficient method for DNA sequencing 
which enables the detection of variants in the tumour DNA. Several commercial 
platforms are currently available and can be used to sequence the complete genome 
(WGS) or specific areas of interest (whole exome sequencing and targeted gene 
sequencing) (Behjati and Tarpey, 2013).  The highly sensitive variant calling of NGS 
provides an accurate means for the detection of specific mutations in relation to disease 
such as identifying cancer driver mutations within the primary tumour and plasma of 
cancer patients (Dawson et al., 2013). Targeted NGS is a further refined sequencing 
method where pre-determined gene panels are utilised for the detection of variants 
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(Kaisaki et al., 2016). This provides a cost-effective means with relatively short 
turnaround time which can be implemented into clinical practice (Rohland and Reich, 
2012). The availability and utility of commercially available target enrichment kits has 
streamlined the sample processing and library preparation (Linnarsson, 2010). The 
addition of Unique Molecular Identifiers (UMI) during the target enrichment steps prior 
to amplification reduces PCR errors and overall increases the specificity of detecting 
low frequency variants (Kou et al., 2016).  
 
Read depth (coverage) is a measure of accuracy for the DNA libraries fragments (reads) 
to align with the reference genome. The higher the read depth the higher the sensitivity 
for variant identification. By utilising a gene panel during sequencing, a higher 
coverage can be obtained ultimately increasing the accuracy of variant detection 
especially in low Mutant Allele Frequency (MAF) samples. Weerts et al. (2017) utilised 
a targeted 45 gene panel of common cancer variants for sequencing DNA from primary 
tumour DNA and serum ctDNA in 10 metastatic breast cancer patients. Weerts et al. 
(2017) identified matching somatic mutations between the primary tumour DNA and 
ctDNA to a minimum MAF threshold of 2%. Nevertheless, sample availability and 
integrity have the potential to reduce sequencing efficiency as Weerts et al. (2017) 
acknowledge the MAF of metastatic driver mutations can potentially be as low as 
0.01%. 
 
1.2.3.4 Mutation Quantification 
Polymerase Chain Reaction (PCR) methods such as quantitative PCR (qPCR) have 
become gold standard procedures for quantifying complimentary DNA and genomic 
DNA (Taylor, Laperriere and Germain, 2017). A very high sensitivity is required for 
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the quantification of extremely low levels of tumour DNA amongst normal background. 
Earlier versions of PCR require stringent optimisation procedures, normalisation and 
external controls, which thereby limits their sensitivity for quantification of rare mutant 
targets in ctDNA analysis (Hindson et al., 2011). 
Sykes et al. (1992) were the first to describe a PCR method using “limiting dilution” 
and Poisson statistics for the quantification of a specific target out of background noise. 
This was further developed by Vogelstein and Kinzler (1999) for the quantification of 
rare mutant targets using a separation and amplification technique so only mutant or 
wild-type PCR products of the desired DNA target are present. Two further 
methodologies arose from this initial digital PCR procedure: droplet digital PCR 
(ddPCR) and BEAMing (Beads, Emulsion, Amplification and Magnets). Both forms 
have since been commercialised, BEAMing by Sysmex Inostics, Illinois USA and 
droplet digital PCR by Bio-Rad Laboratories, California, USA and RainDance 
Technologies, Massachusetts, USA.  
Previous studies such as Higgins et al., (2012) have demonstrated the high sensitivity of 
the BEAMing protocol in ctDNA analysis. Higgens and colleagues were able to detect 
one mutant copy of a PIK3CAvariant in 10,000 wild type copies (DNA molecules). 
However, its complex methodology is a hindrance for efficient turnaround time for 
clinical decision making (Hindson et al., 2011). 
 
The commercial BioRad ddPCR platform uses microfluidics to generate 20,000 
droplets per well from an oil-master mix emulsion. The master mix consists of an 
aqueous solution termed ‘Supermix’, sample DNA, target forward and reverse primers 
and fluorescent bound wild type (HEX), and mutant (FAM) probes. These droplets are 
then amplified on a thermocycler prior to the amplification of the fluorescent labels on a 
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designated droplet reader machine (Fig 1.9) The amplitude data for both wild type and 
mutant targets are analysed in two optical channels. Data analysis using the QuantaSoft 
Pro™ software can be implemented to determine the concentration of both wild type 
and mutant version of the target in copies per microlitre. While previous studies have 
demonstrated a high sensitivity for mutant detection (Miotke et al., 2014), this is target 
specific and ultimately depends on the efficiency of assay design.  Further limitations of 
this technique include the need to pre-determine targets within samples prior to 
quantification and the lack of multiplexing for numerous variant targets within a single 
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1.2.4 Clinical Decision Making  
Quantification of ctDNA in cancer patients will ultimately provide clinicians with 
molecular snapshots of the cancer dynamics over a given patient’s course of disease. 
Fluctuating ctDNA concentration is representative of tumour burden and the patient’s 
response to treatment. Furthermore, metastatic dissemination can be monitored in 
patient’s post-surgical removal of their primary tumour (Bratman et al., 2015). In breast 
cancer, monitoring ctDNA levels in high risk, early-stage patients has been correlated 
with high sensitivity for predicting breast cancer relapse (Garcia-Murillas et al., 2015). 
 
1.2.5 Summary  
The review of previous studies that have employed ctDNA analysis indicates that 
sample processing using plasma, centrifugation methods and the Qiagen CNA 
extraction kit are all suitable for ctDNA analysis in the New Zealand context. However, 
the use of specialist cfDNA blood collection tubes, targeted NGS for mutation 
identification and ddPCR for mutation quantification require optimisation and 
validation within the New Zealand context.  
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1.3 Aims and Objectives 
The first aim of this thesis it to contribute to the development of ctDNA as a cancer 
surveillance clinical tool for New Zealand cancer patients. This aim will be met by  
1) minimising pre-analytic factors that affect sample collection and stability for 
prolonged periods,  
2) optimisation of mutation identification via targeted NGS and quantification using 
ddPCR will ascertain sensitivity detection limits for future clinical samples.  
 
The second aim of this thesis is to conduct a small pilot study of ctDNA in metastatic 
breast cancer patients. Analysis of ctDNA in this patient group will test the future 
clinical protocol as well as investigate if ctDNA detects a clinical response earlier than 
standard clinical practices. 
 
  




Chapter 2  
Materials and Methods 
 
2.1 Materials  
2.1.1 Equipment 
0.2 mL 8 well PCR Tube Strip - 4titude, England 
1.7 mL microfuge tube - SorensonTM BioScience, Inc. USA 
10 mL Strippets - Griener Bio-one, Austria 
15 mL Centrifuge Tubes - Griener Bio-one, Austria 
50 mL Centrifuge Tubes - Griener Bio-one, Austria 
96 well plates - Bio-Rad Laboratories, USA 
C1000 Touch™ Thermal Cycler (96 Deep-well Reaction Module) - Bio-Rad 
Laboratories, USA 
Cell Free DNA BCTs - Streck, USA 
Cell Free DNA Blood Collection Tubes - Roche, Switzerland 
Contherm Thermotec 2000 Oven - Contherm Scientific Ltd, New Zealand 
DG32TM Cartridges for AutoDG - Bio-Rad Laboratories, USA 
Eppendorf Centrifuge 5417C - Eppendorf, Germany 
Eppendorf Centrifuge 5810R - Eppendorf, Germany 
Fume Cupboard 326h - Thermoplastic Engineering Ltd, New Zealand 
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Glass Cover Slips - Esco Optics Inc, USA 
K3EDTA Vacutainer Glass Blood Collection Tubes - Becton Dickerson and Company, 
USA 
Leica HI1210 Water Bath – Bio-Strategy, New Zealand 
Leica RM 2125RT Sectioner – Bio-Stratergy, New Zealand 
Microscope Slides HistoBand (Adhesion of Tissue Sections) - Marienfeld, Germany 
MicroTUBE AFA Fibre Snap-Cap - Covaris, USA 
MicroTUBE-15 AFA Beads - Covaris, USA 
MiSeq System - Illumina, USA 
Olympus DP71 camera - Olympus, Japan 
Olympus Inverted Microscope IX71 - Olympus, Japan 
Olympus Microscope BX51 - Olympus, Japan 
Pierceable Foil Heat Seals - Bio-Rad Laboratories, USA 
PX1™ PCR Plate Sealer - Bio-Rad Laboratories, USA 
QX200 AutoDG ™ Droplet Digitial ™ PCR System – Bio-Rad Laboratories, USA 
QX200 Droplet Reader ™- Bio-Rad Laboratories, USA 
S220 Focused-ultrasonicator - Covaris, USA 




Automated Droplet Generator Oil for Probes - Bio-Rad Laboratories, USA 
ddPCR TM Supermixes for Probes (No dUTPs) - Bio-Rad Laboratories, USA 
ddPCR ™ Droplet Reader Oil - Bio-Rad Laboratories, USA 
DPX Mountant for Histology - Sigma Aldrich, USA 
Eosin Y Solution - Sigma Aldrich, USA 
Ethanol (Absolute) - Lab Supplies, New Zealand 
Ethanol (Analytic Grade) - Lab Supplies, New Zealand 
Human Genomic DNA - Roche, Switzerland 
Mayer's Haematoxylin Solution - Sigma Aldrich, USA 
UltraPure TM DNase/RNase Free Distilled Water - Thermo Fisher Scientific, USA 
Xylene - Scharlau Chemicals, Spain 
 
2.1.3 Commercial Kits  
GeneRead FFPE DNA Kit - Qiagen, Germany 
High Sensitivity DNA Analysis Kit - Agilent Technologies, USA 
MiSeq Reagents Kit v2 – Illumina, USA  
Multiplex I cfDNA Reference Standard Set - Horizon, England 
QIAmp Circulating Nucleic Acid Kit - Qiagen, Germany 
QIASeq Targeted DNA Panels (Human Breast Cancer Panel) - Qiagen, Germany 
Qubit TM dsDNA High Sensitivity Kit - Thermo Fisher Scientific, USA 
SureSelectXT Reagent Kit- Agilent Technologies, USA  
ThruPLEX ® Tag-Seq Kit - Rubicon Genomics, USA 
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2.1.4 DNA Primers and Probes 
Primers  
DNA Oligo Forward & Reverse Primers BARD1 p.Arg658Cys.215595164, Integrated 
DNA Technologies Inc, USA 
DNA Oligo Forward & Reverse Primers BRCA1 p.His117fs.41256229, Integrated 
DNA Technologies Inc, USA 
DNA Oligo Forward & Reverse Primers CDH1 p.Vak391fs.68847248, Integrated DNA 
Technologies Inc, USA 
DNA Oligo Forward & Reverse Primers KMT2C p.Gly838Ser.151945007, Integrated 
DNA Technologies Inc, USA 
DNA Oligo Forward & Reverse Primers NRAS p.Gln61Lys.114713909, Integrated 
DNA Technologies Inc, USA 
DNA Oligo Forward & Reverse Primers PIK3CA pGlu545Lys.179218302, Integrated 
DNA Technologies Inc, USA 
DNA Oligo Forward & Reverse Primers TP53 p.Tyr220Cys.7578190, Integrated DNA 
Technologies Inc, USA 
DNA Oligo Forward & Reverse Primers TP53 p.Val97fs.7579398, Integrated DNA 
Technologies Inc, USA 
 
Probes  
PrimeTime 5' 6-FAM/ZEN/3’ IBFQ BARD1 p.Arg658Cys.215595164, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5' 6-FAM/ZEN/3’ IBFQ BRCA1 p.His117fs.41256229, Integrated DNA 
Technologies Inc, USA 
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PrimeTime 5' 6-FAM/ZEN/3’ IBFQ CDH1 p.Vak391fs.68847248, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5' 6-FAM/ZEN/3’ IBFQ KMT2C p.Gly838Ser.151945007, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5' 6-FAM/ZEN/3’ IBFQ NRAS p.Gln61Lys.114713909, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5' 6-FAM/ZEN/3’ IBFQ PIK3CA pGlu545Lys.179218302, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5' 6-FAM/ZEN/3’ IBFQ TP53 p.Tyr220Cys.7578190, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5'HEX/ZEN/3’ IBFQ BARD1 p.Arg658Cys.215595164, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5'HEX/ZEN/3’ IBFQ BRCA1 p.His117fs.41256229, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5'HEX/ZEN/3’ IBFQ CDH1 p.Vak391fs.68847248, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5'HEX/ZEN/3’ IBFQ KMT2C p.Gly838Ser.151945007, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5'HEX/ZEN/3’ IBFQ NRAS p.Gln61Lys.114713909, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5'HEX/ZEN/3’ IBFQ PIK3CA pGlu545Lys.179218302, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5'HEX/ZEN/3’ IBFQ TP53 p.Tyr220Cys.7578190, Integrated DNA 
Technologies Inc, USA 
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PrimeTime 5’ 6-FAM/ZEN/3’ IBFQ TP53 p.Val97fs.7579398, Integrated DNA 
Technologies Inc, USA 
PrimeTime 5’HEX/ZEN/3’ IBFQ TP53 p.Val97fs.7579398, Integrated DNA 
Technologies Inc, USA 
 
2.1.5 Software 
Agilent 2100 Expert Software - Agilent Technologies, USA 
IMB SPSS Statistics Software (Ver. 23) - IBM Corporation, USA 
IX2-BSW (Ver. 01.03) - Olympus, Japan 
QuantaSoftTM Software - Bio-Rad Laboratories, USA 
R - RStudio Inc. USA 
 
2.1.6 Web Portals 
Bio-Rad Droplet DigitalTM PCR Assays - Mutation Detection (https://www.bio-
rad.com/digital-assays/#/assays-create/mutation)  
gnomAD browser beta http://gnomad.broadinstitute.org/  
Illumina BaseSpace Sequence Hub 
(https://basespace.illumina.com/run/37851831/QSM_BRC_CRC)  
NCBI PrimerBLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) 
Primer3Plus (http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) 
Qiagen QIAseq DNA Enrichment (https://www.qiagen.com/nz/shop/genes-and-
pathways/data-analysis-center-overview-page/qiaseq-targeted-dna-panels-analysis-
center/?instrument=Illumina_MiSeq&catno=DHS-001Z)  
UCSC Genome Browser (https://genome.ucsc.edu)  
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2.2  Methods 
2.2.1 Ethical approval and recruitment of healthy volunteers and cancer 
patients  
Ethical approval was obtained from the Ministry of Health; Health and Disability 
Ethics Committees (reference number LRS/09/05/018/AM04) for using samples from 
healthy volunteers for the development of blood and urine markers for cancer. Twenty 
healthy volunteers were recruited; those who were pregnant, sick (self-reported 
symptoms for the common flu or cold) or presently taking prescription medication were 
excluded. Ethical approval for the pilot study of ctDNA analysis in metastatic breast 
cancer patients was obtained from the New Zealand Multi - Region Ethics Committee 
(reference number MEC/09/06/060). Patients were recruited from two study locations 
within New Zealand; Auckland (Dr. Annette Lasham, University of Auckland) and 
Dunedin (Professor Parry Guilford, University of Otago). Consent for the use of 
Formalin-Fixed Paraffin Embedded (FFPE) tumour tissue and collection of blood 
samples was obtained from patients by their respective Oncologists. Eighteen patients 
who had undergone surgical removal of their primary tumour and were receiving 
chemotherapy treatment agreed to take part in this study. Findings from six patients 
based in Dunedin (SDHB) are included in this thesis as at the time of writing this 
thesis, tumour blocks had not yet been obtained for the remaining patients. 
 
2.2.2 Comparison of two commercial cfDNA blood collection tubes 
2.2.2.1 Sample Collection 
Blood was drawn from the recruited healthy volunteers by venepuncture into 5X Cell 
Free DNA BCTs® (Streck, USA ref. 218961) and 5X Cell Free DNA Blood Collection 
Tubes® (Roche, Switzerland ref. 778566601) by a licensed phlebotomist at Southern 
Community Laboratories (Dunedin, New Zealand). One volunteer also had blood 
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drawn into 10X 2 mL Vacutainer® K3EDTA Tubes (Becton Dickerson and Company, 
USA ref. 367839)  
Blood was drawn to fill the tubes (~8.5-10 mL) as per the manufacturer’s 
recommendations and brought back to the processing laboratory (Cancer Genetics 
Laboratory, Department of Biochemistry, University of Otago) for storage and 
processing. 
 
2.2.2.2 Sample Storage and Processing  
Samples were stored upright in a test tube rack in a Styrofoam container placed in a 
temperature (22° C) regulated room. Samples were processed on days 0, 4, 7, 10 and 14 
post collection with day 0 samples processed within 2 hours of blood draw. The plasma 
was separated from the red blood cells (RBC) by centrifugation in an Eppendorf 
Centrifuge 5810R. The samples were first spun down at a speed of 200 rcf then at 1600 
rcf for 10-minute intervals with both break and acceleration set at zero. The plasma was 
transferred into 15 mL Centrifuge Tubes (Griener Bio-one, Austria) and spun again at 
1600 rcf to remove intact white blood cells (Dhallan et al., 2004). Cell Free DNA was 
extracted from the healthy volunteer plasma using the QIAmp Circulating Nucleic Acid 
Kit (Qiagen, USA ref.QIA5514) as per the manufacturer's protocol for 4 mL of plasma. 
Modifications to the provided protocol involved using an Eppendorf 5417C centrifuge 
set to 18,000 rcf and 20,000 rcf to draw Buffer ACW1, ACW2 and Absolute Ethanol 
(100%) through the QIAamp Mini Column rather than the vacuum pump. The final 
DNA was eluted in 35 µL of UtraPure DNase/RNase Free Distilled Water (Thermo 
Fisher Scientific, USA ref. 1097715) rather than the provided Buffer AVE. 
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2.2.2.3 Quantification of cfDNA in Blood Collection Tubes  
Concentration of circulating DNA eluted from the plasma was measured using the 
Qubit 2.0 Fluorometer with the dsDNA High Sensitivity Kit (Thermo Fisher Scientific, 
USA ref. Q32854) as per the manufacturer's protocol. Two microlitres of the DNA 
sample was diluted in 198 µL of dsDNA HS buffer and reagent and then measured 
against the provided DNA standards in ng/µL. The final concentration (ng/mL of 







Fragment size profiling of the eluted DNA was carried out by capillary electrophoresis, 
using the 2100 Bioanalzyer with the High Sensitivity DNA Analysis Kit (Agilent 
Technologies, USA ref. 50674626). Samples were diluted to 1ng/µL and loaded onto 
the HS dsDNA chip with the appropriate reagents and run on the system as per the 
manufacturer’s protocol. The 2100 Expert Software was used to generate an 
electropherogram which quantified DNA fragments as fluorescent peaks 
(mass/molarity) at various base pairs (bp) in length between two markers (lower = 
35bp, upper = 10, 380bp). This provided a visual representation of circulating DNA in 
relation (~165bp in length) to genome DNA (gDNA) contamination (>2000bp in 
length). 
 
2.2.2.4 Statistical Analysis  
A comparative analysis between samples was conducted using the IBM SPSS (Ver21) 
statistical software using a paired samples student t test. Confidence intervals (95%) 
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were plotted using Standard Error of Mean (SEM). The mean differences were 
considered to be statistically significant if the associated P values were less than or 
equal to 0.05. The Bonferroni Correction method was applied in this scenario to correct 






2.2.3 Optimisation of mutational quantification methods  
ctDNA yield and concentration vary significantly in clinical samples, thereby limiting 
the ability to detect low mutant allele frequency samples. A commercial cfDNA 
reference standard set (Horizon, England ref. HD780) with known mutations at various 
allele frequencies was used to test the limit of detection for mutation quantification in 
NGS library preparation and ddPCR. 
 
2.2.3.1 Identification of minimum input DNA amounts (ng) for satisfactory read 
depth in Next Generation Sequencing 
The 1% allele frequency sample (40 ng/µL) was diluted with UltraPure water into 0.2 
mL PCR tubes (4titude, England) to give a final DNA amount of 20 ng, 5 ng and 1 ng. 
One hundred and thirty microliters of genomic DNA (gDNA) from pooled healthy 
individuals (Roche, Switzerland ref. 11691112001) was fragmented to 150 bp using the 
Covaris Focused-ultrasonicator (Covaris, USA) with the appropriate protocol for the 
microTUBE AFA Fibre Snap-Cap (Covaris, USA). The concentration of gDNA was 
measured using the Qubit 2.0 Fluorometer and the dsDNA HS Kit (Thermo Fisher 
Scientific, USA) prior to dilution to give a final DNA amount of 20 ng. Samples were 
prepared for library preparation, amplification and target enrichment using the 
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ThruPLEX ® Tag-Seq Kit (Rubicon Genomics, USA ref. R400427) and SureSelectXT 
hybridisation panel (Agilent Technologies, USA ref. HEWL519U4816) as per the 
manufacturer’s protocol. A custom gene panel consisting of 578 cancer genes was used. 
The gene list was acquired from SeqCap EZ Designs - Comprehensive Cancer Design 
(Roche, Switzerland). Dr. Rob Day (PhD, Research Fellow), sequenced the samples 
using the Illumina Mi-Seq platform with the Mi-seq Reagents v2 (Illumina, USA ref. 
MS1022002). The Illumina Isaac Enrichment v2.1 app was used to analyse the data and 
create enrichment reports. 
 
2.2.3.2 Optimisation of ddPCR assay design for high sensitivity  
The Horizon Multiplex 1 cfDNA Reference Standard Set® was used for assay 
optimisation and to identify the background mutation threshold for the Bio-Rad ddPCR 
system (Bio-Rad, USA). The cfDNA reference samples contain known mutation in 
genes EGFR, KRAS, NRAS and PIK3CA at mutant allele frequencies of 5%, 1% and 
0.1% along with a wild type sample. (Appendix B). 
 
2.2.3.3 Primer and Probe Design 
The primers and probes for each ddPCR assay was designed using Primer3Plus 
(Untergasser et al., 2012). Sequence data for both mutant and wild type allele variants 
was obtained from Bio-Rad’s Mutation Detection Droplet Digital TM PCR Assays 
(Bio-Rad, 2017). BioRad recommends the following parameters as optimal for RED 
assay design. In Primer3Plus, the task was set to detection and in general settings the 
product range was set to 60-200 bp long. Primer size ranged from 15-36 bp in length 
with the optimal length set to 20 bp. The melting temperature of the primers ranged 
between 50oC to 65oC with the optimal temperature set to 60oC. The concentration of 
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divalent cations and dNTPs was set to 3.8 mM and 0.8 mM, respectively. The 
thermodynamic parameters and salt correction formula were both as per SantaLucia 
(1998). Length of the probes spanned 15-27 bp with 20 bp being the optimal length. 
The melting temperature was set between 62oC to 70oC with the optimal temperature at 
63oC. The concentration of the divalent cations and dNTP for the probes was set as per 
the primers. All primer and probe products were checked for target specificity using 
NCBI PrimerBLAST (Ye et al., 2012). Primers and probes were purchased from 
Integrated DNA Technologies, USA at a stock concentration of 100 nM and diluted to 
a working concentration of 20 nM upon arrival. Probes were ordered with the reporter 
fluorophores dyes FAM (mutant) and HEX (wild type) along with the double quencher 
ZEN™ and the 3’ Iowa Black FQ which increases detection sensitivity and lowers 
background interference. The sequence data for forward and reverse primers and wild 
type and mutant probes for two variants, NRAS 61K and PIK3CA E545K are presented 
below (Table 2.1). 
 
Table 2.1 Primers and Probes Sequence for NRAS Q61K and PIK3CA E545K  
 
 




























2.2.3.4 Temperature Gradient  
Assays were run on the C1000 Touch™ Thermal Cycler (Bio-Rad, USA) with a 
gradient temperature setting to determine the optimal temperature for separation of the 
droplets. A 17X mastermix for each assay (Table 2.2) was made up and 13.53 µL 
pipetted into 16 wells of a 96 well plate. The Wild Type and 5% reference samples (40 
ng/µL) were diluted to 2 ng/µL and 3 µL pipetted in 16 wells each. Droplets were 
generated using the Qx200 AutoDG™ Digital Droplet ™ PCR System with settings 
and reagents set for “Probes”. Post droplet generation, the 96 well droplet plate was 
sealed, and samples run on a C1000 ™ Thermal Cycler with set protocols (Table 2.3). 
The gradient temperature function was used in the annealing/extension step with a 
temperature range between 52oC and 62oC (Table 2.4). Droplets were read on the 
QX200 ™ Droplet Reader ™ and the results analysed using the Quantasoft ™ 
Software.  
 




Reagent VOLUME  (µl) 1X
Supermix for Probes 
(No dUTPs) 11
Primer - F 0.99
Primer - R 0.99
Probe - Wt 0.275
Probe - Mt 0.275
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Table 2.3 Thermocycler protocol for temperature gradient 
 
 
Table 2.4 Temperature gradient for the 96-well plate 
 
 
2.2.3.5 Assay Set Up  
Prior to ddPCR set up, genomic DNA was fragmented to 150 bp using the Covaris 
S220 Ultrasonicator as mentioned previously and its was concentration measured using 
the Qubit 2.0 Fluorometer and dsDNA HS assay. Genomic DNA (gDNA) was diluted 
to a working concentration of 3.07ng/µL while the reference standards were diluted to 
Cycle Step Temperature Time 
Enzyme Activation 95◦C 10:00 min 
Denaturation 94◦C 0:30 sec
Annealing/Extension 52◦C – 62◦C 1:00 min 














4 ng/µL. All ddPCR assays were prepared in a pre-PCR amplification room to 
minimize cross-contamination. Prior to droplet generation, a 34X mastermix (Table 
2.2) was prepared and 13.53 µL pipetted into 32 wells of a 96-well plate (Bio-Rad, 
USA). Three microlitres of reference standard DNA and gDNA was added to the wells, 
the plate was sealed with a PCR Thermal Seal RT2KK™ (Excel Scientific Ltd, USA) 
before centrifuging briefly in a Select Spin Plate Centrifuge (Select BioProducts, USA). 
Samples were generated into droplets using the QX200™ AutoDG™ Droplet Digital™ 
PCR System (Bio-Rad, USA) as per the manufacturers specifications for “Probes” 
reagents. PCR amplification of droplets was carried out using the C1000 Touch ™ 
Thermal Cycler as shown in Table 2.3. An alteration to the protocol was that the 
annealing/extension temperature was set to 61.4ºC for the NRAS Q61K assay and 
60.1ºC for the PIK3CA E545K assay, the optimal temperature as determined in the 
previous gradient temperature run. Post amplification, target wild type and mutant 
concentration were quantified using the QX200™ Droplet Reader (Bio-Rad, USA). 
The experiment type was set to Rare Event Detection (RED) and the super-mix type set 
to ‘Probes (no dUTPs)’. Fluorescent probes measured were HEX for the wild type 
target and FAM for the mutant target. The raw results were then exported into 
Quantasoft Pro Software (Bio-Rad, USA) for data analysis.  
 
2.2.3.6 Analysis of Amplitude Data using the “twoddPCR” R package 
To compare the analysis of the data to determine the original concentration of the 
targets of interest, a comparison analysis between Quantasoft Software (Biorad, USA) 
and an open source R package “twoddPCR” (Chui et al., 2017) were carried out. The 
raw amplitude data were first exported from the QX200™ Droplet Reader software and 
imported into R (Rstudio Inc, USA) for both the previously described NRAS and 
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PIK3CA assay runs. Droplets were classified using the “kmeansClassify” method to 
separate out the droplets into four clusters; Negative Negative (NN), Negative Positive 
(NP), Positive Negative (PN) and Positive Positive (PP). These clusters were based on 
the droplets containing either the channel 1 target (mutant), channel 2 target (wildtype), 
both targets or neither targets (empty droplets). The “MahanobisRain” function was 
used to remove ambiguous droplets between the four major clusters and the 
“maxDistances” variable, which corrects for the furthest distance a droplet can be from 
the cluster’s central point and adjusted to 35 for all cluster groups. Droplet plots were 
generated using the “dropletPlot” function (Appendix B) and a summary table 
consisting of the number of droplets in each channel and the corresponding 
concentrations (copies/µL) of both wild type and mutant targets in the samples was 
exported into a .csv file. The final analysis was carried out in Microsoft Excel 
(Microsoft, 2016). The concentration was averaged across the number of wells per 
sample. Concentration in copies per microlitres (copies/µL) were plotted using Excel’s 
graph function for each sample (NTC, gDNA, gDNA+0.1%, gDNA+1% and 
gDNA+5%). The 95% confidence intervals were calculated using the 
“binom.test(Number of positive droplets, Total number of droplets)$conf_int” function 
in R and shown as error bars.  
 
2.2.4 Clinical application of ctDNA analysis in New Zealand metastatic breast 
cancer patients  
2.2.4.1 Sample Collection  
Patients undergoing chemotherapy treatment had blood samples drawn into two Roche 
Cell Free DNA Blood Collection Tubes prior to receiving chemotherapy treatment. 
Patients having treatment through the Southern District Health Board had blood 
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samples drawn by a registered nurse and samples were brought back to the processing 
laboratory (Cancer Genetics Laboratory, University of Otago, Dunedin) where they 
were centrifuged as per Dhallen et al., (2004). Plasma was stored in 15 mL centrifuge 
tubes (Greiner Bio-One, Germany) at -80oC until further processing. FFPE tumour 
blocks were obtained through Southern Community Laboratories. Several blocks per 
patient were selected based on each patient’s pathology reports. This was carried out by 
a research assistant from the Department of Surgical Sciences, University of Otago. 
Tumour blocks were stored in the Cancer Genetics Laboratory at room temperature 
until further processing.  
 
2.2.4.2  FFPE Tumour Tissue Sample Processing  
Tissue Micro-sectioning 
Tumour Blocks were sectioned using a Leica RM 2125RT Sectioner (BioStratergy, 
New Zealand). Sections used for Haematoxylin and Eosin (H&E) staining were cut to 
5µM thickness, while sections for DNA Extraction were cut to 10 µM thickness. 
Sections were placed in a Leica HI1210 Water Bath (Bio-Strategy, New Zealand) set to 
42oC to disperse the tissue for 30 seconds - 1 min prior to mounting onto a microscope 
glass slide (Marienfeld, Germany). Sections were dried in a Contherm Thermotec 2000 
Oven (Contherm Scientific Ltd, New Zealand) at 52oC for 3 hours before being stored 
in a microscope slide box at room temperature. 
 
Haematoxylin and Eosin Staining 
Tumour tissue sections were stained with Mayer’s Haematoxylin Solution (Sigma 
Aldrich, USA ref. MH532) and Eosin Y Solution (Sigma Aldrich, USA ref. HT110116) 
to differentiate cancerous tissue from normal tissue. As shown in Table 2.5, samples 
were stained in a Fume Cupboard 326h (Thermoplastic Engineering Ltd, New 
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Zealand). The stained tissue was then mounted with DPX Mountant for Histology 
(Sigma Aldrich, USA), a xylene based mounting medium prior to applying a glass 
coverslip (Esco Optics, USA) over the sample. The prepared slides were then left to dry 
in the Fume Cupboard for 1-3 hours. Samples were then examined using an Olympus 
Microscope BX51 (Olympus, Japan) to identify cancerous areas for DNA extraction. 
Imaging of the samples were carried out using an Olympus Inverted Microscope IX71 
(Olympus, Japan) with the Olympus DP71 camera (Olympus, Japan) and IX2-BSW 
(Ver. 01.03) imaging software (Olympus, Japan). 
Table 2.5 Protocol for H&E staining of FFPE tumour tissue sections
 
 
Procedure Solution Time 
Deparaffinisation 
Xylene 2X Changes 10 min Each 
Absolute Ethanol (100%) 2X 
Changes 5 min Each 
95% Ethanol 5 min
Rehydration
70% Ethanol 3 min 
Wash Distilled Water 3 min 
Stain Mayers’ Haematoxylin Solution 5 min 
Wash Running Tap Water 8 min 
Ethanol Rinse 
70% Ethanol 5 min 
95% Ethanol 1 min 
Counter Stain Eosin Y Solution 10 sec 
Dehydration
95% Ethanol 2X Changes 5 min each 
Absolute Ethanol 2X Changes 5 min each 




Tumour DNA was extracted using the Qiagen GeneRead DNA FFPE Kit (Qiagen, 
Germany ref. QIA180134). For each patient, 2-3 slides were used per tumour block to 
optimise DNA yield. Using the H&E stained slides as a guide, the cancer tissue was 
carefully scraped off the extraction slides into a collection tube and the extraction 
process carried out as per the GeneRead DNA FFPE kit’s protocol. A slight alteration 
to the manufacturers recommendations involved eluting the final DNA with UltraPure 
water rather than the provided ATE Buffer. The concentration of the eluted DNA was 
measured using the Qubit 2.0 Fluorometer with the dsDNA High Sensitivity kit. For 
any samples with a concentration of less than 5 ng/mL, the sectioning and staining 
process as above was repeated with new tumour blocks in order to acquire sufficient 
DNA. For each patient, sections from 1-3 blocks were used depending on their 
respective H&E staining.  
 
2.2.4.3 Library Preparation & Target Enrichment  
Sequencing libraries were prepared by diluting FFPE DNA samples to 5 ng/µL with a 
final working volume of 16 µL. One microlitre of sample was used for capillary 
electrophoresis analysis using the Agilent 2100 Bioanalyzer with the High Sensitivity 
DNA analysis kit. As FFPE DNA consisted of very large fragments, samples were 
mechanically sheared to ~200bp using the S220 Ultra-Sonicator (Covaris, USA) with 
the appropriate protocol for the 15 µL MicroTUBE-15 AFA Beads tubes (Covaris, 
USA). The QIAseq Targeted DNA Panel (Human Breast Cancer) (Qiagen, Germany 
ref. DHS-001Z) was used for sample library construction and target enrichment as per 
the manufacturer’s protocol. 
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Sequencing 
The libraries were then quantified using the Qubit 2.0 Fluorometer with the dsDNA HS 
kit. Samples were then diluted to approximately 4 nmol and run on the bioanalyzer as 
previously stated. Individual patient libraries were combined into a breast cancer 
enriched library for a total volume of approximately 6 µL. Three microlitres of the 
breast cancer enriched library were then combined with 3 µL of a colorectal cancer 
patient library to make a 4 nM mix of all patient libraries. Five microlitres of the 
combined libraries were then added to 5 µL of 0.2 M sodium hydroxide (NaOH), 
vortexed briefly and left at room temperature for five minutes. 990 µL of Hybridization 
Buffer (Illumina, USA) was added to the denatured libraries to make a final stock 
concentration of 20 picoMolar (pM) of which 8 pM was loaded into a MiSeq v2 
reagent cartridge and run on the Illumina Mi-seq platform (Illumina, USA). The output 
“.fastq” sequence files were downloaded from the Illumina Basespace Sequence Hub 
(Illumina, 2017) and uploaded to the Qiagen QIASeq DNA Enrichment Portal (Qiagen, 
2017). DHS-001Z (Breast Cancer) was selected for the QIASeq DNA Catalouge 
Number and the File Lane was set to 1 Lane (Mi-seq Platform) and all the breast cancer 
read files selected. Jobs were then created for all the breast cancer samples and on 




All mutation data were first sorted for each individual patient, followed by passing all 
variant calling filters, before sorting by Variant Mutant Frequency (VMF) from highest 
(1.0) to lowest (0). Mutations where chosen with a VMF between 0.1-0.45 or 0.6-0.85. 
Mutations with a VMF of 0.46-0.55 or 0.95-1.0 were ignored as they were highly likely 
to be heterozygous or homozygous germline mutations. Mutations were then sorted 
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based on their percentage in the general populations using the gnomAD browser (Broad 
Institute, 2017). Previously published mutations had either a COSMIC number or a 
reference SNP (rs) ID number which could be inputted into the database to provide 
population percentage. New mutations were looked up based on their mutation location 
on their corresponding chromosome. Only mutations that made up a very small 
proportion of the general population (i.e < 0.01) were put forward as possible 
contenders for ddPCR assay design. 
 
Primer and Probe Design for Clinical Sample Variants 
Primers and probes were designed using Primer3Plus as previous with the set 
recommendations from Bio-Rad (Appendix B). All primers (Table 2.5) and probes 
(Table 2.6) were ordered from IDT at the same concentrations and probe bound 
fluorophores and quenchers as previously stated (see section 2.2.3.2). 
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Table 2.6 Forward and reverse primer sequences for variants in clinical samples  
 
 
































Table 2.7 Wild type and mutant probe sequences for variants in clinical samples  
 
  
Patient Id Mutation Probes 
BRC001 TP53 V97fs
Wild Type:





























2.2.5 ctDNA Analysis in Plasma Samples 
2.2.5.1 DNA Extraction 
Circulating DNA was extracted using the QIAmp Circulating Nucleic Acid Kit as per 
the 5 mL of plasma protocol. As previously stated, deviations from the standard 
protocol involved using an Eppendorf 5417C centrifuge set to 18,000 rcf and 20,000 rcf 
to draw Buffer ACW1, ACW2 and absolute ethanol (100%) through the QIAamp Mini 
Column rather than the vacuum pump. The final circulating DNA was eluted in 45 µL 
of UltraPure water rather than the provided Buffer AVE. However, if less than 4 mL of 
clinical sample plasma was available, the final circulating DNA was eluted in 35 µL of 
UltraPure water. 
 
2.2.5.2 ddPCR Temperature Gradient 
All samples were run through a temperature gradient PCR step to identify the optimal 
temperature of droplet separation specific to each mutation assay. Patient FFPE DNA 
was diluted to 1 ng/uL and fragmented gDNA (150 bp) was diluted 1:50 to 0.614 
ng/µL. A mastermix of supermix for probes (no dUTPs), forward and reverse primers, 
mutant and wild type probe and UltraPure™ water was made for each mutation assay 
(Table 2.2). Twenty microlitres of mutation specific mastermix was pipetted into 16 
wells of a 96 well plate (BioRad, USA) and this was repeated for each mutation assay 
for each patient. Two microlitres of gDNA was pipetted into 8 wells per assay and 
corresponding 2 µL of mutation specific FFPE DNA into 8 wells per assay.  Droplets 
were created using the AutoDG™ prior to running samples on the C1000x Cycler with 
a temperature gradient of 52ºC – 62ºC (Table 2.3). The droplet reader was then used to 
quantify the concentration of both the wild type and mutant copies at various 
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temperatures (Appendix C). The optimal temperature was then selected for each assay 
for plasma sample analysis (Table 2.8). 
 
Table 2.8 Optimal droplet separation temperature for the clinical sample ddPCR assays 
 
  
Patient Id Assay Optimal Droplet Separation Temperature  
BRC001 TP53 V95fs 58.2oC
BRC005 TP53 Y220C 56oC
BRC006 CDH1 V391fs 58.2oC
BRC007 KMT2C G838S Heterozygous Germline Mutation 
BRC009 BARD1 R658C Cross Reactivity of Probes 
BRC010 BRCA1 H117fs 52.7oC
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2.2.5.3 Quantification of ctDNA in plasma samples 
For each patient, an assay specific mastermix was prepared. Six microliters of 
UltraPure water were pipetted into two wells as the non-template control (NTC), 6 uL 
of gDNA was pipetted into 4 wells as the negative control and 6uL of FFPE DNA 
pipetted into 2 wells as the positive control. Six microlitres of plasma ctDNA was then 
pipetted into 3 wells per chemotherapy cycle. Samples were then run through the 
AutoDG machine and then on the C1000x™ thermocycler with the appropriate 
temperature as identified previously (Table 2.8). Post-PCR amplification, samples were 
run on the Droplet Reader for data analysis. The raw data was then analysed using 
Quantasoft Pro ™ Software to determine the concentration of each patient’s mutant 
target relative to the corresponding wild type in copies per microlitre. Data was 
exported into Excel, where standard deviation and standard error of the mean was 
calculated. Line graph were generated using Excel ‘graph’ function where the 
concentration of the mutant target was plotted against the various cycle samples. 









ctDNA: Method Enhancement 
 
A lack of standardised operating protocols for ctDNA analysis is a barrier for its 
clinical utility. This thesis aimed to optimise the general methodology pipeline in 
an effort to develop ctDNA analytics as a clinical surveillance tool for New 
Zealand cancer patients. This study targeted three areas where potential sample 
variability could have a detrimental effect on further down-stream analysis and 
final clinical outcomes. These are sample collection and storage, mutation 
identification, and quantification. Healthy volunteer blood samples and a 
commercially available cfDNA reference standard set was used to develop 
guidelines and recommendations for future clinical sample studies. In this chapter 
the results pertaining to identifying an optimal cfDNA blood collection tube and the 
optimisation of variant identification and quantification methods are presented. 
These findings will be implemented in the pilot ctDNA breast cancer study, the 
results which are presented in the following chapter.  
 61 
3.1  Comparison of cfDNA Blood Collection Tubes  
3.1.1 Study Rationale 
The rural locality of many New Zealand cancer patients is a barrier to their access 
to specialist healthcare. Surveillance of cancer progression and response to 
treatment through a minimally invasive means such as ctDNA analysis will reduce 
the impact patient locality has on cancer care.  
 
Regular analysis of ctDNA requires blood samples to be drawn from patients via 
venepuncture into pressurised collection tubes consisting of an anti-coagulant 
buffer such as potassium ethylenediamine tetra-acetic acid (K3EDTA) or Heparin. 
However, collection tubes with heparin anti-coagulant have been shown to have 
inhibitory effects on downstream PCR analysis for plasma DNA (Beutler, Gelbart 
& Kuhl, 1990). International ctDNA studies identified the short sample storage 
period of K3EDTA tubes as a significant disadvantage for the future clinical 
application of this method. Samples drawn into K3EDTA tubes must be processed 
within 24 hours of collection to prevent significant gDNA contamination (Chan et 
al., 2005). Furthermore, shipment of samples to distant processing laboratories 
experience variable conditions such as constant agitation and fluctuating 
temperatures, which are known to increase WBC lysis significantly (Norton et al., 
2013). Therefore, the use of collection tubes containing preservation buffers which 
stabilise the sample under such conditions is essential for future clinical sample 
collection.  
 
Streck Cell Free DNA BCTs® (Streck, USA) are blood collection tubes with a 
proprietary stabilisation buffer, intended for the collection, shipping and storage of 
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whole blood samples. Samples drawn into these tubes are stable for up to 14 days 
post collection within 6ºC-37ºC. Extensive validation studies against standard 
K3EDTA tubes have shown significant reductions in gDNA release due to WBC 
lysis under various sample shipment conditions (Norton et al., 2013). A similar 
product; Roche Cell Free DNA Collection Tubes® (Roche, Switzerland) have since 
become commercially available for blood sample collection. The Roche tubes also 
contain a stabilisation buffer and claim to prevent gDNA release for up to 7 days 
post collection under various shipment conditions. At the time of this study (2016) 
no comparisons have been made between the Streck and Roche tubes in respect to 
sample stability.  
 
The purpose of this study was to compare the Roche Cell Free DNA Collection 
Tubes® against the current “gold standard” Streck Cell Free DNA BCTs® to 
determine any significant difference between the two tube types for their 
performance regarding sample stability. The results of this study will inform the 
choice of a collection tube for sample collection in the pilot ctDNA breast cancer 
clinical application study. Comparisons were made between the two tubes for the 
mean concentration of total circulating DNA and level of gDNA contamination at 
room temperature. A 14-day post collection period was used in this study as this 
would allow adequate time for samples to be shipped from rural localities within 
New Zealand to a distant processing laboratory. A further observational study was 
carried out to compare cfDNA collection tubes against standard K3EDTA tubes 
which lack the preservation buffer present in the Roche and Streck tubes. 
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3.1.2 Mean DNA Concentrations of Samples Stored in Streck and Roche 
Tubes Over a 14 day Period. 
Blood was drawn from 20 healthy volunteers recruited for this study into 5X Streck 
Cell Free DNA BCT ® and 5X Roche Cell Free DNA Collection Tubes® per 
volunteer. Samples were stored at room temperature (20ºC) and processed at five 
different time points (Day 0,4,7,10 and 14 post collection). Samples were centrifuged 
to separate the plasma from the red blood cells (RBC) and the ctDNA extracted using 
the Qiagen QIAmp Circulating Nucleic Acid Kit as per the manufacturer's protocol 
for 4 mL of blood plasma. The DNA was eluted into 35 µL of UltraPure™ water and 
quantified using the Qubit 2.0 Fluorometer with the dsDNA High Sensitivity Kit. 
The concentration data were entered into Excel spreadsheets and statistical analysis 
carried out using IBM SPSS (ver23) Statistical Software.  
 
The findings of this experiment showed that the concentration of DNA eluted from 
samples stored in Streck and Roche Blood Collection tubes were within the expected 
normal range of cfDNA in healthy individuals (Table 3.1 and 3.2) (Anker et al., 
1999). A comparison between the mean concentrations and 95% Confidence 
Intervals plotted as error bars of cfDNA in the two tubes is shown in Fig 3.1. 
A paired student t-test was carried out to compare the mean for each tube type at the 
five different time points. Only the day 0 samples were significantly different 
However, on applying the Bonferroni Adjustment (Miller, 1966) for multiple 
comparisons, where the new P-value threshold for observed statistical significance is 
≤ 0.0025, none of the paired samples were statistically different (Table 3.3). 
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Table 3.1 Mean concentrations of plasma DNA from 20 healthy volunteers stabilized in 
Streck tubes over 14 days 
 
Table 3.2 Mean concentrations of plasma DNA from 20 healthy volunteers stabilized in 
Roche tubes  
 
Table 3.3 Paired student t test for the comparison of the mean DNA concentration of 
samples stabilized in Streck and Roche blood collection tubes  
 
Day Mean SD St Error of Mean
0 5.70 3.11 0.70
4 6.00 1.68 0.38
7 7.24 1.86 0.42
10 6.92 2.90 0.65
14 6.60 3.06 0.68
Day Mean SD St Error of Mean
0 4.96 2.90 0.65
4 6.22 2.28 0.51
7 6.86 2.27 0.51
10 6.84 2.00 0.45











Day 0 0.74 1.54 0.34 2.16 0.04
Day 4 -0.22 1.90 0.43 -0.51 0.62
Day 7 0.38 1.96 0.44 0.87 0.39
Day 10 0.08 2.37 0.53 0.16 0.88





Figure 3.1 A comparison of the mean concentration of plasma DNA (ng/mL) from 20 
healthy volunteers stabilised in Streck and Roche cfDNA blood collection tubes. Samples 
were processed at five different time points over a 14 day period post collection. Error bars 
indicate 95% confidence intervals.  
 
Figure 3.1. A comparison of the mean concentration of plasma DNA (ng/mL) from 20 
healthy volunteers stabilised in Streck and Roche cfDNA blood collection tubes. Samples 
were processed at five different time points over a 14 day period post collection. Error bars 
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3.1.3 Capillary Electrophoresis Analysis of Eluted DNA to Determine Level of 
gDNA Contamination  
Total DNA was measured using the Qubit 2.0 Fluorometer. To distinguish 
between cfDNA and gDNA and to identify gDNA contamination over the various 
time points, capillary electrophoresis was carried out using the Agilent 2100 
Bioanalyzer system with a High Sensitivity DNA Kit. Samples were diluted to 1 
ng/µL and loaded onto the microfluidic chips as per the manufacturer’s 
recommendations. The analysis was carried out using the Agilent 2100 Express 
Software and electropherograms generated per sample and the fragment sizes of 
the DNA were measured against fluorescence intensity (FU) (Panaro et al., 2000). 
Previous studies have identified the majority of cfDNA fragments are 
approximately 165 bp in length, whilst gDNA consist of longer fragments, 
generally greater than 2000 bp in length (Mouliere and Rosenfeld, 2015; 
Underhill et al., 2016).  
 
Representative electropherograms for two volunteers (Streck =1; Roche=1) for 
their respective “Day 0” and “Day 14” samples are shown in Fig 3.2. The Streck 
tube results for Day 0, show a cfDNA peak between 150-200 bp at 40 FU (Fig 
3.2A). It was observed that gDNA at 10 FU was already present in this sample 
(Fig 3.2B). Phlebotomy blood draw technique was deemed as a plausible reason 
for this early presence of gDNA. In the volunteer’s day 14 sample, the 
fluorescence level of cfDNA had decreased to 20 FU, but the fluorescence level of 
gDNA appeared to remain constant from the day 0 sample. For the Roche tubes, 
the volunteer’s day 0 sample had a cfDNA peak between 150-200bp at 40 FU (Fig 
3.2C). By the fourteenth day, cfDNA peak had decreased to 20 FU and low-
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Figure 3.2 Electropherogram graphs from healthy volunteers’ samples stored in Streck 
and Roche collection tubes. DNA peaks are quantified between two markers, lower (35 bp) 
and upper (10, 380 bp). cfDNA peak for each volunteer was identified between 150-200 bp. 
Genomic DNA peaks clustered around the upper marker and consisted of peaks greater than 
200 bp. Graphs are shown for two volunteers A. Streck Day 0 sample, volunteer had a 
significant cfDNA peak along with two smaller peaks at 375 bp and 500 bp. It was unclear 
whether these peaks were short gDNA fragments. Peaks close to the upper marker were 
characterized as gDNA. B. Streck Day 14 sample, cfDNA size peak had decreased in 
fluorescence, however the two previously observed peaks were still apparent. gDNA near the 
upper marker was at the same fluorescence intensity as the day 0 sample. C. Roche Day 0 
sample, a significant cfDNA peak was apparent. No gDNA was observed near the upper 
marker. D. Roche Day 14 sample, fluorescence of cfDNA has diminished, slight gDNA 
contamination apparent in this sample compared to the day 0 sample 
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Comparisons of the average length of cfDNA and gDNA fragments and the percentage 
of their corresponding fluorescent peaks in the total sample are presented in Tables 3.4 
and 3.5. Both the Streck and Roche blood collection tubes had distinctive cfDNA 
fragment peaks between 140-180 bp in length. Samples with gDNA contamination had 
gDNA fragments ranging between 4000-6000 bp in length. In the total sample, cfDNA 
in both tubes made up 30-45% of the total DNA, while gDNA made up <20%. 
Furthermore, these percentages were relatively consistent over the 14-day period as no 
significant decrease in cfDNA or increase in gDNA were observed. 
 
Table 3.4 Average fragment length of cfDNA and its percentage of fluorescence within 
the total sample for both Streck and Roche collection tubes 
 
 
Table 3.5 Average fragment length of gDNA and its percentage of fluorescence within 
the total sample for both Streck and Roche collection tubes 
 
  
Average length of cfDNA (bp)
Tube Day 0 Day 4 Day 7 Day 10 Day 14
Streck 167 35% 159 28% 166 26% 147 26% 163 31%
Roche 162 46% 175 40% 169 37% 177 33% 175 33%
Average length of gDNA (bp)
Tube Day 0 Day 4 Day 7 Day 10 Day 14
Streck 5228 13% 4796 13% 5239 14% 5324 15% 6895 15%
Roche 4553 16% 4649 14% 5115 14% 5272 12% 5278 17%
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3.1.4 Comparison of Streck and Roche Blood Collection Tubes with 
K3EDTA Blood Collection Tubes 
Previous studies have compared Streck against the commonly used K3EDTA 
collection tubes (Becton Dickinson, USA) (Barret et al., 2011; Norton et al., 2013; 
Wong et al., 2013 and Kang et al., 2016). At the time of conducting this study, no 
previous publication had compared K3EDTA tubes against the Roche tubes.  
To achieve this, blood samples from one volunteer were stored in K3EDTA and the 
concentration of DNA compared against the results for the volunteer’s Streck and 
Roche tubes (Fig 3.3).  Samples in K3EDTA tubes showed a substantial increase in 
total DNA from day 7 onwards. As these tubes only contain an anticoagulant 
powder and no preservation buffer, the increase in concentration was attributed to 
lysis of WBC over time.  
 
Figure 3.3 Comparison of sample stability and integrity in specialised cfDNA 
collection tubes against standard K3EDTA tubes. Blood was drawn from a single 
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Capillary electrophoresis analysis for the cfDNA peak in the K3EDTA tubes ranged 
between 170 bp-183 bp over the 14 days (Table 3.6) while gDNA fragments ranged 
between 4190 bp and 5824 bp (Table 3.7). The fluorescence of the cfDNA peak on the 
day 0 sample measured 18 FU and made up 48% of the total sample. The fluorescence 
decreased to 8% by the end of the 14-day period (Fig 3.4A).  Furthermore, gDNA 
initially present had fluorescent peaks <10 FU and made up 13% of the total sample. 
By day 14, the amount of gDNA had increased considerably, peaking at 2000 FU and 
contributing 54% to the total sample (Fig 3.4B). 
Table 3.6 Length of cfDNA fragments and percentage of fluorescence in the total sample 
from one healthy volunteer in Streck, Roche and K3EDTA blood collection tubes 
 
 
Table 3.7 Length of gDNA fragments and percentage of fluorescence in the total sample 
from one healthy volunteer in Streck, Roche and K3EDTA blood collection tubes 
 
Length of cfDNA (bp) 
Tube Day 0 Day 4 Day 7 Day 10 Day 14




171 50% 178 48% 182 56% 181 47% 183 33%
BD Vacutainer 
® EDTA tubes 175 48% 170 9% 178 11% 177 11% 183 8%
Length of gDNA (bp)
Tube Day 0 Day 4 Day 7 Day 10 Day 14




7070 29% 6003 11% 6542 16% 6458 11% 6526 11%
BD Vacutainer 





Figure 3.4 Electropherogram for volunteer’s sample in K3EDTA tubes. A. The day 0 sample 
had a cfDNA peak between 100-200bp in length. No gDNA contamination was identified within 
the sample. B. The day 14 sample had significant amount of gDNA observed at the upper marker. 
Smaller peaks were identifed between 200 bp and 2000 bp, however it is unclear if these are 
short gDNA fragments.   
 
Figure 3.4. Electropherogram for volunteer’s sample in K3EDTA tubes. A. The day 0 sample 
had a cfDNA peak between 100-200bp in length. No gDNA contamination was identified within 
the sample. B. The day 14 sample had significant amount of gDNA observed at the upper marker. 
Smaller peaks were identifed between 200 bp and 2000 bp, however it is unclear if theese are 














3.2 Identification of Minimum Input DNA Amounts for Targeted 
Next Generation Sequencing  
3.2.1 Study Rationale  
The clinical utility of sequencing DNA from cancer patients enables a more sensitive 
and specific approach for the identification of particular cancer mutations (Cottrell et 
al., 2014). Since the human genome was first sequenced (Wheeler et al., 2008), the 
development of the technology has improved remarkably, with several sequencing 
platforms readily available for incorporation within a research laboratory. Targeted 
Next Generation Sequencing utilises specific gene sequencing panels for the 
identification of variants with a recognised connection to a particular disease 
(Illumina, 2017). The use of targeted sequencing for clinical cancer samples will not 
only reduce the cost of sequencing but also enable easier data analysis (de Leng et al., 
2016). Samples for sequencing are typically DNA from FFPE tumour blocks or fresh 
frozen tissue (FF). Obtaining adequate amounts of FFPE tumour DNA is challenging, 
as factors such as cancer type, size of the tumour, number of sections available and age 
of tumour blocks can contribute to low sample input and integrity (Chen et al., 2015). 
Coverage read depth is a measure of how many times a target region aligns to the 
reference genome (Illumina, 2017). The more “coverage” or depth a read has, the 
higher the accuracy for variant calling. However, the detection of somatic mutations 
within the samples may be hindered by their low mutant allele frequencies. Therefore 
identifying minimum thresholds  for clinical sample input and allele frequency will 
provide guidance for future analysis.  
 
The purpose of this study was to compare various input amounts of tumour DNA to 
determine the average read depth and variant calling (number of mutations detected) 
compared to a normal gDNA. cfDNA reference standards were used in this experiment 
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with known mutations and mutant allele frequencies (5%, 1% and 0.1%). Three 
reference samples (20 ng, 5 ng and 1 ng) at 1% mutant allele frequency (MAF) were 
prepared for sequencing along with pooled healthy gDNA (20 ng). Sequencing 
libraries were made using the Thruplex® Tag-seq Kit (Rubicon, USA) and target 
enrichment using the SureSelectXT kit (Rubicon, USA) with the custom gene panel 
obtained from the Comprehensive Cancer Design gene list (Roche, Switzerland). 
Samples were sequenced using the Illumina Mi-Seq platform which has both high 
sensitivity and a fast turnaround of data analysis (Quail et al., 2012). The results of 
this study will help provide guidance for future clinical FFPE tumour DNA extraction, 
subsequent sequencing and data analysis.  
 
3.2.2 Mean Target Coverage Depth and Mutation Detection   
The enrichment report provided analytic outputs such as mean target coverage depth, 
read enrichment, and the number of mutations detected. The number of reads 
presented from the report have passed the quality filter. A summary of these results is 
shown in Table 3.8. Mean target coverage depth refers to the number of times the 
reads within the target region, align to the reference genome. From the results, the 
gDNA (20 ng) sample had the highest mean target coverage depth, while the reference 
samples (20 ng, 5 ng and 1 ng) coverage depth decreased as the amount of DNA 
reduced (Table 3.8). Samples with low coverage as observed for the 5 ng and 1 ng 
samples are less reliable regarding sensitivity and specificity of the sequence data. The 
number of variants detected within the genes (includes introns, exons and UTR 
regions) for each sample are presented in Table 3.9. All the samples had similar range 
of SNVs detected, which is likely due to normal germline variation. The reference 
samples, however, showed a decreasing trend in the number of insertions and deletions 
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identified. Thus, as the biological complexity of the samples decreases so does the 
mean coverage depth and the number of mutations identified. However, both the 20 ng 
and 5 ng sample had a similar number of “variants by consequence” detected 
(Appendix B) 
 
Table 3.8 The mean target coverage depth and read enrichment of gDNA and cfDNA 
reference standards samples  
 
 

























20 ng 107.9 8466 3882834 2751506 70.86%
5 ng 62.2 8466 2781253 1630108 58.61%
1 ng 18.1 8466 1099054 493784 44.93%
Sample Amount SNV Insertions Deletions





20 ng 1912 128 583
5 ng 2565 103 245
1 ng 1571 57 133
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3.3 Optimisation of ddPCR assays  
3.3.1 Study Rationale  
Droplet digital PCR is the most recent development of quantitative PCR (qPCR) for 
the quantification of DNA targets. The clinical application of ddPCR analysis will 
enable the direct quantification of specific cancer-related mutations in clinical 
samples. The sensitivity and specificity of the technology can be optimised to identify 
rare mutant alleles at very low mutant frequencies, a requirement for clinical sample 
analysis (Jones et al., 2014). Optimised assays have been demonstrated to accurately 
detect mutant targets at allele frequencies of 0.001 % (Hindson et al., 2011; BioRad, 
2017)  
Ideally, in a diagnostic scenario, results from the ddPCR analysis of patient ctDNA 
within their plasma will facilitate clinical decision making for patients such as 
response to treatment and metastatic relapse. This study aimed to investigate the 
ability of in-house designed ddPCR assays to detect ctDNA at low mutant allele 
frequencies (5%, 1% and 0.1%) within a high background of normal gDNA (10,000 
wildtype copies) 
3.3.2 ddPCR Analysis of NRAS Q61K and PIK3CA E545K in cfDNA 
Reference Standards  
In-house ddPCR assays were designed for two mutations within the commercial 
cfDNA reference standards (NRAS Q61K c.181C>A and PIK3CA E545K 
c.1633G>A). These standards are generated from human cancer cell lines and 
fragmented to approximately 160bp to match the size of ctDNA. The standards consist 
of 8 variants (Appendix B) at different mutant allele frequencies (5%. 1% 0.1% and 
Wt). Reference ctDNA was spiked into pooled normal gDNA to mimic clinical 
samples. gDNA was used as a negative control and to identify the background 
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threshold of the mutation in the pooled healthy sample. ddPCR was carried out using 
the BioRad Laboratories QX200 ddPCR System with Automated Droplet Generator.   
 
The final results were quantified using QuantaSoft Pro ™ Software, where the end 
point fluorescence wavelength of the two reporter dyes (FAM and HEX) were 
measured in intensity (amplitude) to discriminate between the MT and WT target. 
Poisson Statistics and 95% total confidence intervals were generated automatically by 
a proprietary based algorithm within the software. The standard deviation was 
calculated by exporting the individual well data into Excel (Microsoft, 2016) and 
using the “STDEV.S” function. Significant results were identified by comparing the 
95% confidence intervals (Poisson statistics and total error) of the spike in sample 
against the negative control (gDNA). Any overlap between the error bars of the 
samples and the negative control is indicative of a false positive rather than a true 
result. Non-Template Controls (NTC) were used to measure sample preparation 
technique. The fractional abundance was calculated for each sample and is the 
percentage of mutant copies out of the total reaction. This value provides a measure of 
sensitivity for each assay.  
 
The concentration of the NRAS Q61K wild-type and mutant target in the gDNA and 
the reference spike in samples are presented in Table 3.10. Threshold settings in the 
1D amplitude window showed a single mutant positive droplet in one NTC well at 
~3500 fluorescence amplitude. This is indicative of cross-contamination within the 
assay run. However, as all other NTC wells were subsequently clear of any 
contamination, it was decided that the threshold for this well would be set slighter 
higher (3500 amplitude). The majority of the positive mutant droplets in the gDNA 
and reference standards were above 4000 fluorescence amplitude. The total number of 
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wild-type copies for each reaction was ~10, 000 copies (concentration (copies/µL) x 
reaction volume (22 µL)) for all the samples (excluding the NTC). Significant results 
were observed for all three spike-in samples for the NRAS assay as there was no 
overlap of the errors bars (Fig 3.5)  
 
The concentration of the PIK3CA E545K wild-type and mutant target (copies/µL) for 
the gDNA and the reference spike in samples are presented in Table 3.11. Both the 5% 
and 1% spike in samples had significant results for mutant target detection.  However, 
the 0.1% spike in sample had an overlap of error bars with the negative control (Fig 
3.5). This indicates that the ctDNA levels within this sample were too low for the 
assay to differentiate from the background mutation rate of the gDNA. Therefore, this 
particular assay can reliably detect the PIK3CA E545K mutation ins samples ≥ 1% 
MAF but not ≤0.1%.  
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Table 3.10 Concentration of NRAS Q61K mutant and wild type targets in gDNA and 
cfDNA reference standards 
 
 
Table 3.11 Concentration of PIK3CA E545K wild type and mutant targets in gDNA and 















NTC 0 0 0 0 0
gDNA 431 0.0178 114.7 0.12 0.004
0.1% + gDNA 492 0.153 272.8 0.37 0.031
1% + gDNA 438 0.849 129.2 0.47 0.193













NTC 0 0 0 0 0
gDNA 175 0.312 8.53 0.10 0.178
0.1% + gDNA 226 0.207 25.05 0.13 0.103
1% + gDNA 226 1.12 6.88 0.23 0.496
5% + gDNA 211 3.33 17.3 0.50 1.557
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Figure 3.5. Concentration of the mutant targets of NRAS Q61K (A) and PIK3CA 
E545K (B) ddPCR assays. A. The NRAS assay shows significant results as the error 
bars of the spike-in samples do not overlap those of the gDNA. B. The PIK3CA assay 
showed significant results for the 1% and 5% reference standard spike in samples. The 
error bars of the 0.1% sample overlapped those of the gDNA negative control and were 
identified as statistically non-significant based on the Poisson and Total error calculated 
by Quantasoft Pro™  
 
 
Figure 3.5. Concentration of the mutant targets of NRAS Q61K (A) and PIK3CA 
E545K (B) ddPCR assays. A. The NRAS assay shows significant results as the error 
bars of the spike-in samples do not overlap those of the gDNA. B. The PIK3CA assay 




























































3.3.3 Analysis of ddPCR raw data using the “twoddPCR” R package 
As the algorithms in the QuantaSoft Pro™ software is proprietary and therefore not 
publically characterised, it was decided to compare its analytic capability with a 
recently published R package known as “twoddPCR”. This R package uses a k-
means clustering methodology for grouping the PCR droplets into four groups; 
positive Mt & positive Wt (PP), positive Mt & negative Wt (PN), negative Mt & 
positive Wt (NP) and negative Mt & negative Wt (NN). A further parameter, known 
as “MahalanobisRain” refines the four groups by removing ambiguous droplets, 
known as “Rain” that doesn’t fall into any of the cluster groups (Chiu et al., 2017). 
The output from the twoddPCR analysis is produced for individual wells. The data 
was exported into Excel where the target concentration for each well was averaged 
for each sample and the standard deviation calculated. 
 
The concentration of the NRAS Q61K wild-type and mutant targets are presented in 
Table 3.12. Comparisons with the data analysed using the QuantaSoft Pro ™ 
software showed differences for calculated concentrations of the gDNA sample and 
the reference standard samples. The contamination of one droplet in one NTC well, 
however, was classified as positive for both WT and MT targets, which is more 
likely to be a false positive rather than DNA contamination as observed in the 
QuantaSoft Pro™ analysis. Furthermore, variances in the fractional abundance for 
each sample were observed. The only sample that had a similar fractional abundance 
to the QuantaSoft Pro software calculation was the 0.1% spike-in sample. This is 
most likely due to droplet classification and the algorithms used for such analysis.  
The concentration of the calculated by twoddPCR for the PIK3CA E545K assay are 
presented in Table 3.12. As observed in the QuantaSoft Pro™ results, the 0.1% spike 
in sample had a lower detected concentration than the gDNA negative Table 3.13). 
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Furthermore, the fractional abundance values also varied, and as previously stated, is 
likely due to how the droplets are classified. Additionally, the 95% confidence 
intervals calculated for the twoddPCR analysis were significantly lower than those 
determined by QuantaSoft Pro™ (Fig 3.6) 
 
Table 3.12 Concentration of NRAS Q61K wild type and mutant targets in gDNA and 
cfDNA reference standards using the twoddPCR R package 
 
 
Table 3.13 Concentration of the PIK3CA E545K wild type and mutant targets in 















NTC 0.018 0.018 0.036 0.036 50
gDNA 436.75 0.019 118 0.037 0.003
0.1% + gDNA 499 0.15 115 0.10 0.031
1% + gDNA 475.4 0.82 272.6 0.37 0.172













NTC 0 0 0 0 0
gDNA 177.8 0.18 8.95 0.03 0.101
0.1% + gDNA 242 0.12 16.8 0.13 0.053
1% + gDNA 231 0.97 7.04 0.26 0.418
5% + gDNA 216.3 3.16 18.5 0.49 1.450
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Figure 3.6 Concentration of mutant targets of NRAS and PIK3CA assays as 
quantified by “twoddPCR” R package. Confidence intervals (95%) were calculated 
using the “binom.test” function in R and plotted as error bars. A. A single positive mutant 
droplet was identified in the NTC, which may be a false positive. Significant results were 
observed for all three cfDNA reference standard spike in samples. B. Significant results 
were observed for 1% and 5% spike in samples. The background rate of the mutation in 




Figure 3.6. Concentration of mutant targets of NRAS and PIK3CA assays as 































































Chapter 4  
ctDNA Analysis in Metastatic Breast Cancer 
 
4.1 Background 
Metastatic or stage IV cancer is the primary cause of death in breast cancer patients 
(Redig and McAllister, 2013). Widely acknowledged as incurable in the majority of 
cases, metastatic disease is the result of disseminated cancer cells from the primary 
tumour to distant sites within the organism (Chambers, Groom and MacDonald, 
2002). Treatment for such patients involves a combination of both palliative and 
adjuvant therapy for the management of adverse symptoms (Sledge, 2016). Current 
methods for surveillance of disease progression include imaging techniques  such as 
ultrasounds, MRI, CT and PET scans over the patient’s course of treatment.  
 
A provisional report on the standard of service for breast cancer patient was 
published by the New Zealand Ministry of Health (2009). Good practice 
recommendations include utilising tumour markers in conjunction with radiological 
scans for the surveillance of advanced breast cancer patients, particularly for those 
who have “non-measurable metastatic disease”. 
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4.1.1 Study Rationale 
The purpose of this study was to explore the utility of ctDNA analysis for the 
surveillance of metastatic breast cancer in New Zealand patients. This study aimed to 
monitor metastatic tumour burden and investigate whether ctDNA analysis could 
determine a response to treatment earlier than current clinical practices such as 
radiological scans. 
 
4.1.2 Study Design 
Eighteen metastatic breast cancer patients were enrolled in this study. Eleven patients 
were based in Dunedin (SDHB) and seven were based in Auckland (ADHB). The 
results for six Dunedin based patients will be presented in this thesis as these patients 
were the only ones who had primary FFPE tumour blocks available and had provided 
at least 4 plasma samples at the time of this research. The clinical information and 
consent for these six patients were obtained by Rachel McLay-Barnes, Research 
Oncology Unit (Dunedin Public Hospital, SDHB), prior to their participation in the 
study. 
 
Patients had blood samples drawn into Roche Cell Free DNA Collection Tubes® by a 
registered nurse prior to receiving chemotherapy or hormone therapy. Samples were 
processed and the plasma stored at -80ºC until enough cycles (more than four cycles) 
were obtained for further analysis. Patient primary tumour blocks were acquired from 
Southern Community Laboratories and cut into 5 µm sections for H&E staining and 
10 µm sections for tumour DNA extraction. Tumour DNA was extracted using the 
Qiagen GeneRead DNA FFPE kit and prepared for targeted sequencing using the 
Qiagen QIASeq Human Breast Cancer Panel and sequenced on the Illumina MiSeq 
platform. Potential mutation candidates were identified for each patient and ddPCR 
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assays were designed in-house and ordered from IDT. ctDNA was extracted from 
patient plasma using the Qiagen QIAmp Circulating Nucleic Acid kit. The 
concentration of the eluted DNA is presented in Appendix C. ddPCR was carried out 
using the BioRad QX200™ AutoDG™ Droplet Digital™ PCR system. The wild type 
and mutant fluorescence amplitudes were quantified using QuantaSoft Pro™ 
software. Patient FFPE tumour DNA (1 ng/µL) was used as respective positive 
controls and healthy pooled gDNA (1 ng/µL) as the negative controls. Fractional 
abundance of the mutant target in relation to the total reaction (wild-type and mutant) 
was calculated for each sample and presented as a percentage (%). The clinical 
information and  results from the ctDNA analysis will be presented for each patient 




4.2 Case Study of Six Metastatic Breast Cancer Patients  
4.2.1 Patient BRC001 
Clinical Presentation 
Patient BRC001 is a 55 year-old female who was diagnosed with breast cancer in 
2014. The patient underwent a right mastectomy for the subsequent removal of her 
primary tumour in November 2014. Histopathological analysis classified the tumour 
as poorly differentiated and between 2-5 cm in size. The patient also presented with 
cancer spread into her regional lymph nodes. Immunohistochemistry showed the 
primary tumour was HER2 receptor positive but negative for the oestrogen and 
progesterone receptors (ER and PR). 
 
Treatment and CT Scans  
The patient was first treated with adjuvant radiotherapy of 50 Gray (Gy) in 25 
fractions and this regime was completed by August 2015. Following this, the patient 
was treated with a chemotherapy regime of adjuvant 5-fluorouracil, epirubicin, 
cyclophosphamide (FEC) and docetaxel for 6 cycles. The patient was also treated 
with the anti-HER2 drug tratstuzumab (Herceptin®) for a year. 
Metastatic disease was diagnosed in the patient in December 2016, within the 
patient’s right internal mammary chain lymph nodes. After this diagnosis the patient 
was treated with palliative radiotherapy of 20 Gy in 5 fractions. A CT scan post 
radiotherapy identified a “hypodense heterogeneous area” in the patient’s anterior 
mediastinum. Dimensions of this lesion measured approximately 3.8 x 5 cm, however 
it was unclear whether this lesion was in fact metastatic. 
 
The patient was recruited into the ctDNA breast cancer study in February 2017. At 
this time, the patient also commenced treatment with pertuzumab, vinorelbine and 
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trastuzumab. Pertuzumab acts by inhibiting HER2/HER3 dimerisation while 
trastuzumab attracts immune cells to the cancer sites and causes degradation and 
cytotoxicity. Vinorelbine is a cytotoxic chemotherapy drug and induces apoptosis 
within the cancer cells (Capelan et al., 2013; Vu and Claret, 2012; Nahta, Hung and 
Estev, 2004). A CT scan in May showed the previously reported lesion within the 
anterior mediastinum had reduced to 2 mm in diameter. A further lesion within the 
patient’s liver, had also decreased from 14 mm to 3 mm. The vinorelbine treatment 
ceased in June 2017, but the patient continued with pertuzumab and trastuzumab for 
the rest of treatment regime.  
 
ctDNA Results 
The patients primary FFPE tumour blocks were sectioned and stained with H&E to 
identify areas of cancerous tissue (Fig 4.1A,B) . These areas were carefully removed 
from the slides and the tumour DNA extracted and sequenced. A novel TP53 variant 
(c.288_289insA, p.Val97fs) was identified (Table 4.1) and an in-house ddPCR assay 
was designed. Eleven blood samples were collected between February and November 
2017 prior to the patient receiving chemotherapy and the ctDNA extracted from the 
plasma. Quantification of the mutant and wild type variant was carried out by ddPCR. 
The concentration of the mutant target in the patients FFPE tumour DNA was 154.9 
copies/µL (Standard Deviation (SD) ± 1.74 copies/µL). The fractional abundance for 
the tumour DNA was 65.2%. No mutant target was detected in the gDNA samples 
(Fig 4.2). Analysis of the plasma samples identified a concentration of 119.57 
copies/mL (SD ± 21.3 copies/mL) in the cycle 1 sample of which the fractional 
abundance was 5.83%. However, for the following 10 cycles, no mutant copies were 
detected (Fig 4.3).  
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Figure 4.1 Primary tumour sections stained with H&E. A) Section at 10X 
magnification. B) Section at 40X magnification. The tumour (DNA stained purple) appears 
to be infiltrating into the surrounding muscle (stained pink).  
 
Figure 4.1 Primary tumour sections stained with H&E. A) Section at 10X 
magnification. B) Section at 40X magnification. The tumour (DNA stained purple) appears 


























Figure 4.2. 1D amplification for TP53 c.288_289inA, p.Val97fs in patient BRC001. 
Samples are presented on the x axis while fluorescence amplitude is presented on the y axis. 
Plasma samples are referred to as C1-C11. A manual thresholds were set (pink line) for both 
channel 1 and 2.  A) Mutant droplets are shown in channel 1 (blue). B).Wild type droplets are 
shown in channel 2 (green). Grey droplets below the threshold are considered as “rain” and are 
not included in the final quantification. A high number of MT droplets are present in the 
positive control wells (FFPE) while none were observed in the negative control wells (gDNA). 
This illustrates that the assay is able to detect both the wild type and mutant target with high 
specificity.  
 
Figure 4.2. ddPCR droplets for TP53 c.288_289inA in patient BRC001. A) Mutant droplets 
are shown in channel 1 (blue). B).Wild type droplets are shown in channel 2 (green). Manual 
thresholds were set at 3000 for wt and 2000 mt amplitude. A high number of mt droplets are 
present in the positive control wells (FFPE) while none were observed in the negative control 
wells (gDNA). This illustrates that the assay is able to detect both the wild type and mutant 





Figure 4.3. Concentration of TP53 c.288_289inA p.V97fs mutant targets in patient 
BRC001 plasma samples (copies/mL). Plasma from eleven chemotherapy cycles were 
analysed (C1-C11). Standard error was calculated and plotted as error bars. Patient 
commenced treatment with pertuzumab and trastuzumab and vinorelbine in April 2017 as 
represented by the green arrow. Patient stopped vinorelbine treatment in June 2017 as shown 
by the red arrow but continued with pertuzumab and trastuzumab for the remainder of her 
treatment regime. In May 2017 CT scan showed a reduction in size of previously observed 
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4.2.2. Patient BRC005 
Clinical Presentation 
Patient BRC005 is a 73 year-old female who was diagnosed with invasive ductal 
carcinoma in her right breast. The patient underwent a mastectomy for the removal of 
her primary tumour in October 2013. Histopathological analysis revealed the tumour 
to be 3.5 cm in size and classified as high grade, poorly differentiated but with no 
lymphovascular invasion. Immunohistochemistry profiling showed the tumour was 
negative for all three hormone receptors (ER-, PR- and HER2-), the molecular 
characteristics of Triple Negative Breast Cancer (TNBC). 
 
Treatment and CT Scans 
The patient was treated with six cycles of adjuvant FEC- docetaxel chemotherapy 
which was completed in April 2014. The patient also completed 40.05 Gy in 15 
fractions of adjuvant radiotherapy by June 2014. Metastatic disease was diagnosed in 
March 2017 in the patient’s left lung. A biopsy taken from this lesion had the same 
triple negative characteristics (ER-, PR- & HER2-) identified in her primary breast 
tumour. A mass within the patient’s right lung was also evident although this 
appeared to improve in following CT scans. The patient joined the ctDNA breast 
cancer study in April 2017 prior to commencing palliative vinorelbine chemotherapy 
for inducing cancer cell death. Following the completion of this treatment in August 
2017 the patient reported to her clinician that she was feeling very well. She was 
subsequently treated with letrozole, a hormone treatment for palliative response 
which commenced in August 2017. Letrozole is an aromatase inhibitor which 
prevents the synthesis of oestrogen. It has been shown to be ineffective in TNBC due 
the cancer cells lacking the appropriate receptors for drug interaction (Leidtke et al., 
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2017). However, the patient was primarily treated letrozole to keep her cancer in 
check and any onset of new symptoms would action a change in treatment. 
 
ctDNA Results  
Tumour sections were stained with H&E prior to removing cancerous tissue and 
extracting the DNA (Fig 4.4A, B). A previously identified TP53 mutation 
(c.659A>G, p.Tyr220Cys) was chosen from sequencing the patient’s tumour DNA 
(Table 4.2).  A wet lab validated ddPCR assay is currently available from BioRad 
Laboratories, however an in-house assay was designed instead to minimize costs and 
reduce turn-around time for assay shipment, validation and clinical data analysis.  
Eight blood samples were collected from the patient between April and August 2017. 
ddPCR analysis in the patient’s primary tumour showed a mutant concentration of 
111.9 copies/µL (SD ± 7.65 copies/µL). The fractional abundance was 27.35%. No 
mutant copies were detected in the gDNA negative control samples (Fig 4.5). In the 
plasma samples. In the patient’s plasma samples, ctDNA concentrations for the TP53 
variant was only detected in cycle 3 (0.90 copies/mL SD ± 1.65 copies/mL) and 7 
(0.83 copies/mL SD ± 1.39 copies/mL) (Fig 4.6). From the previous ddPCR 
optimisation analysis (Section 3.3) it was decided a background mutation rate of ≥ 3 
mutant copies/mL in the plasma samples would be indicative of a true result. As the 
ctDNA in this patient’s samples were below this threshold, these results are 
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Figure 4.4 Primary tumour sections stained with H&E. A) Section at 10X magnification. B) 
Section at 20X magnification. Tumour DNA (stained purple) has infiltrated into the 
surrounding smooth muscle (stained pink).   
 
Figure 4.4 Primary tumour sections stained with H&E. A) Section at 10X magnification. B) 
Section at 20X magnification. Tumour DNA (stained purple) has infiltrated into the 
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B)
Figure 4.5. 1D amplification for TP53 c.659A>G p.Y220C in patient BRC005. Samples are 
presented on the x axis and fluorescence amplitude presented on the y axis. Plasma samples are 
referred to as C1-C8. A manual thresholds were set (pink line) for both channel 1 and 2.  A) Mutant 
droplets are shown in channel 1 (blue). B).Wild type droplets are shown in channel 2 (green). Grey 
droplets below the threshold are considered as “rain” and are not included in the final quantification. 
Single MT droplets were only observed in cycle 3 and cycle 7 plasma samples. A high number of 
MT droplets was observed in the FFPE tumour sample, however, single MT droplets were only 
present in cycle samples 3 and 7. No MT droplets were prsent in the gDNA samples, however a 
single droplet is insufficent to draw conclusions from.    
 
Figure 4.5. ddPCR mutant and wildtype droplets for TP53 Y220C variant in patient BRC005. 
A. Mutant targets in channel 1 (blue). B. Wild type targets in channel 2 (green). The mutation was 





Figure 4.6. Concentration of TP53 c.659A>G p.Y220C mutant target in plasma samples 
of patient BRC005 (copies/mL). Plasma from eight chemotherapy cycles were analysed 
(C1-C8). Standard error was calculated and plotted as error bars. Patient commenced 
palliative vinorelbine in April 2017 (green arrow) and finished in June 2017 (red arrow). The 
patient then commenced treated with letrozole (blue arrow). A CT scan in June 2017, 
observed no measurable metastasis in the patient’s lungs or liver and a previously suspicious 
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4.2.3. Patient BRC006 
Clinical Presentation  
Patient BRC006 is a 59-year-old female with lobular breast cancer who underwent a 
right mastectomy for the removal of her primary tumour in March 2012. 
Histopathology classified the tumour as moderately differentiated, 9 cm in size with 
regional invasion into her surrounding lymph nodes (G2, T3 & N3). 
Immunohistochemistry determined the molecular subtype of the primary tumour as 
ER positive but negative for both the PR receptor and HER2 protein. The patient also 
underwent a precautionary mastectomy of her left breast; however, histopathology 
analysis identified no abnormalities within the breast tissue. 
 
Treatment and CT Scans  
The patient was initially treated with adjuvant FEC-docetaxel chemotherapy for six 
cycles. This was followed by adjuvant radiotherapy and adjuvant letrozole. 
Metastatic disease was diagnosed in August 2016 within the patient’s gastric pylorus. 
A subsequent biopsy identified a poorly differentiated carcinoma, sub-classified as 
ER+, PR- and GATA3+ (GATA-3 Binding Protein). Palliative vinorelbine treatment 
commenced in September and a CT scan in November indicated metastatic bony 
disease, which appeared stable. However, in January 2017, a further scan showed an 
enlarged left para-aortic lymph node and a 1.5 cm sized lesion within the patient’s 
liver. However, no change was apparent in her boney disease. The patient was taken 
off vinorelbine after 6 cycles of treatment and commenced palliative exemestane in 
January 2015, which inhibits the synthesis of extracellular estrogen by inactivating 
the aromatase enzyme (Lonning et al., 2000). A further CT scan in April showed a 
new metastatic lesion in her liver (1.7 cm), but all her previously observed metastasis 
still appeared stable. The patient was recruited into the ctDNA study in May 2017, 
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prior to starting treatment of FEC chemotherapy for 4 cycles, which was completed 
in June 2017. A subsequent CT scan showed a suspicious new lesion in the patients 
left lung, which has yet to be confirmed metastatic. 
 
ctDNA Results 
During the time of ctDNA study, the patient was treated with four cycles of 
chemotherapy, however blood samples from the only last three cycles were available 
for this study. Primary tumour sections were stained with H&E, prior to DNA 
extraction and sequencing (Fig 4.7A, B). A novel CDH1 indel mutation (c.1171delG, 
p.Val391fs) was chosen for ddPCR analysis (Table 4.3). The concentration of the 
patient’s FFPE tumour DNA was 112.42 copies/µL (SD ± 4.84 copies/µL). The 
fractional abundance for the mutant target was 78.82%. No mutant copies were 
present in the gDNA negative control sample (Fig 4.8).  
 
The ctDNA concentration in the patient’s plasma samples for the mutant target was 
117 copies/mL (SD ± 13.83 copies/mL) in cycle 1. This reduced to 0.75 copies/mL 
(SD ± 1.25 copies/mL) by cycle 2. The fractional abundance for the cycle 1 sample 
for the mutant target was 1.76% which reduced to 0.08% by the second cycle of 
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Figure 4.7 Primary tumour sections stained with H&E for patient BRC006. A) Section 
at 20X magnification. B) Section at 40X magnification. Black arrows are pointing at darkly 
stained (purple) cells interwoven in the surrounding muscle tissue (pink).     
 
Figure 4.5 Primary tumour sections stained with H&E for patient BRC006. A) Section 
at 20X magnification. B) Section at 40X magnification. Black arrows are pointing at darkly 
stained (purple) cells interwoven in the surrounding muscle tissue (pink).     
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Figure 4.8 1D amplification for CDH1 c.1171delG, p.V391fs in BRC006. A. Samples are 
presented on the x axis and fluorescence amplitude presented on the y axis. Plasma samples 
are referred to as C1-C8. A manual thresholds were set (pink line) for both channel 1 and 2.  
A) Mutant droplets are shown in channel 1 (blue). B).Wild type droplets are shown in 
channel 2 (green). Grey droplets below the threshold are considered as “rain” and are not 
included in the final quantification. A high number of MT droplets were observed in the 
plasma cycle 1 but this reduced dramatically in the cycle 2 and 3 sample. MT droplets were 
observed in the FFPE samples but not in the gDNA samples which indicate the assay 
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Figure 4.9 Concentration of CDH1 c.1171delG p.V391fs in the plasma samples of 
patient BRC006 (copies/mL). Plasma from three chemotherapy cycles were analysed (C1-
C3) Standard error of the mean was calculated and plotted as error bars. Patient had already 
one cycle of FEC chemotherapy prior to joining this study (green arrow). Treatment was 
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4.2.4. Patient BRC007  
Clinical Presentation 
Patient BRC007 is a 43-year-old female with breast cancer who had a right 
mastectomy to remove her primary tumour in September 2012. The tumour size was 
less than 0.5 cm and histopathological analysis identified no regional lymph node or 
distant metastasis. Further immunohistochemistry analysis indicated the primary 
tumour was positive for HER2 expression and negative for both ER and PR.  
 
Treatment & CT Scans  
The patient was first treated with three cycles of adjuvant taxatere and 
cyclophosphamide (TC) chemotherapy and in conjunction received trastuzumab for a 
year till January 2013. Metastatic disease was diagnosed in March 2017 where a CT 
scan identified areas of “ground-glass opacification” within both her lungs.  While no 
obvious mass was present, it was suggested that lymphangitis carcinomatosis was the 
cause. Further metastatic spread was observed in the patient’s right axillary lymph 
nodes and several lytic lesions were present in her thoracic (T9) and sacral (S1) 
vertebrae. The patient started palliative treatment in May 2017 with pertzumab, 
vinorlebine and trastuzumab. However, the dosage for vinorelbine was reduced by 
10% from cycle 2 onwards. A later CT scan of the patient’s cervical spine showed 
possible metastatic lesions within several vertebrae. A new lesion within the patient’s 
thyroid (1.8 cm x 1.2 cm) was also identified and follow-up assessment by ultrasound 
was recommended. In June 2017, the patient received palliative radiotherapy of 8 Gy 
in 1 fraction for her metastasis in her lumbar and sacral vertebrae. A subsequent CT 
scan showed the previously enlarged right axillary lymph nodes (1.5 cm) had 
returned to their normal size (now 0.06 cm), the “ground glass opacification” present 
in her earlier scans had also since decreased distinctively. However, the lytic lesions 
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in her thoracic vertebrae had since become sclerotic. Further lesions within the 
patient’s sacral vertebrae also presented both lytic and sclerotic changes but overall 
no new bony metastasis was observed 
 
ctDNA Results  
Primary tumour sections stained with H&E are presented in Fig 4.10A, B. A novel 
KMT2C (Lysine N- methyltransferase 2C) variant was identified (c.2512G>A 
p.Gly838Ser) and chosen for ddPCR analysis (Table 4.4). However, running a 
gradient temperature for the assay revealed similar allele concentrations of both wild-
type and mutant targets (Fig 4.11). This indicates that the chosen variant is most 
likely to be a non-pathogenic germ-line mutation and subsequently of no-benefit for 
ctDNA analysis. From the patient’s sequence data, a previously reported PIK3CA 
E545K (c.1633G>A, p.Glu545Lys) mutation was present. The VMF in this patient 
FFPE tumour was 0.091 which is marginally below the cutoff used for choosing 
mutations from the sequence data. However, as this assay was readily available in the 
lab, it was decided to use this assay for the patient’s ddPCR plasma sample analysis. 
 
The concentration of the mutant target in the patients FFPE tumour DNA was 48.7 
copies/µL (SD ± 3.01 copies/µL). No mutant target copies were detected in the 
gDNA sample (Fig 4.7C). The concentration of the mutant target in the cycle 1 
sample was 61.3 copies/mL (SD ± 5.66 copies/mL). This reduced to 0.84 copies/mL 
(SD ± 1.38 copies/mL) by cycle 2. No ctDNA was detected in samples from cycle 3 
to 8. The fractional abundance of the mutant target in the cycle 1 sample was 3.79% 
which reduced to 0.07% by the cycle 2 sample. The cycle 9 sample had a 
concentration of 1.25 copies/mL (SD ± 1.48 copies/mL). However, as this was less 
than 3 copies/mL cutoff, it was unclear if the tumour burden was increasing (Fig 
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4.12). Further analysis of subsequent plasma samples would confirm the nature of 
this observation.  
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Figure 4.10 Primary tumour sections stained with H&E for patient BRC007. A) 
Section at 20X magnification. B) Section at 40X magnification. Darkly stained nuclei of 
cancer cells are sporadic throughout the muscle tissue and fat cells, as shown by the black 
arrow.  
 
Figure 4.8. Primary tumour sections stained with H&E for patient BRC007. A) 
Section at 20X magnification. B) Section at 40X magnification. Darkly stained nuclei of 
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B)
Figure 4.11 1D amplification for PIK3CA c.1633G>A p.E545K in BRC007. Samples 
are presented on the x axis and fluorescence amplitude presented on the y axis. Plasma 
samples are referred to as C1C9. A manual thresholds were set (pink line) for both channel 
1 and 2.  A) Mutant droplets are shown in channel 1 (blue). B).Wild type droplets are 
shown in channel 2 (green). Grey droplets below the threshold are considered as “rain” and 
are not included in the final quantification. A significant number of MT droplets were 
observed in the FFPE plasma cycle 1 samples. However, all following plasma cycles (C2-








Figure 4.12 Concentration of PIK3CA c.1633G>A p.E545K variant in plasma samples 
of patient BRC007. Plasma from nine chemotherapy cycles were analysed (C1-C9). 
Standard error of the mean was calculated and plotted as error bars. Start of treatment is 
indicated by the light green arrow. Vinorelbine was reduced from cycle 2 onwards as shown 
by the dark green arrow. CT scan in June 2017 identifies improvement in lung and lymph 
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4.2.5. Patient BRC009 
Clinical Presentation  
Patient BRC009 is a 49-year-old female diagnosed with inflammatory breast cancer 
in December 2015. A core biopsy of her primary tumour showed a high grade 
infiltrating ductal carcinoma with regional spread to the right axillary lymph node but 
no distant metastasis. The patient had a right mastectomy in April 2016 along with 
clearance of her axillary nodes. Immunohistochemistry analysis identified the tumour 
as ER+ and PR- and HER2-.   
Treatment and CT Scans 
In July 2016, the patient completed adjuvant radiotherapy of 50 Gy in 25 fractions 
prior to commencing adjuvant Tamoxifen treatment. However, in February 2017, an 
abnormal bone scan revealed possible bone metastasis and the patient was 
subsequently treated with letrozole from March to May 2017. In addition, the patient 
was treated with 8 Gy of palliative radiation to her spine in March 2017. A further CT 
scan in May 2017 indicated metastatic spread to multiple skeletal sites and the 
patient’s liver. The patient was then treated with palliative doxorubicin, to which she 
had a positive response as a CT scan in July 2017 revealed the reduction in size of 
numerous metastatic liver lesions. The patient’s bony disease was stable as no 
significant difference was observed for the patient’s bone lesions from previous CT 
scan results.  
ctDNA Results   
Primary tumour H&E staining is presented in Fig 4.13A, B. In the sequenced tumour 
DNA, a novel BARD1 (BRCA1 Associated RING Domain 1) mutation (c.1972C>T, 
p.Arg658Cys) was chosen for ddPCR analysis (Table 4.5). However, after the initial 
temperature gradient assay run, it became evident that the wild type and mutant 
fluorescent probes had cross-reacted with one another. This was confirmed by the 
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significantly high number of droplets consisting of both wild type and mutant targets 
(Fig 4.14). Discussions with Dr. Sol Green a representative of BioRad Laboratories 
confirmed this observation and suggested the gene, and/or the specific location of the 
mutation may have contributed to this event. Therefore, it was decided not to 
continue with this assay. Due to time restrictions for this thesis it was not feasible to 
identify another mutation for clinical sample analysis. 






























Figure 4.13 Primary tumour sections stained with H&E for patient BRC009. A) Section 
at 20X magnification. B) Section at 40X magnification. Infiltration of tumour cells within the 
breast lobules and surrounding muscle tissue as shown by the black arrows.   
 
Figure 4.11 Primary tumour sections stained with H&E for patient BRC009. A) Section 
at 20X magnification. B) Section at 40X magnification. Infiltration of tumour cells within the 
















Figure 4.14 2D amplification plot of the BARD1 c.1972C>T p.A658C mutation in BRC009. 
Amplitude for Channel 1 is measured on the y axis and channel 2 on the x axis. Clusters 
represent the target present within the droplets. Black droplets are considered “empty droplets” 
and contain neither wild type or mutant targets. Green droplets contain only wild type targets. 
Orange droplets contain both wild type and mutant targets. A large cluster of orange droplets 
indicate the presence of both wild type and mutant targets within the droplets, as no mutant only 
targets (blue droplets not shown) are present, this indicates a potential cross-hybridization of the 
two probes. Further investigation regarding this phenomenon is required which is beyond the 
scope of this thesis.     
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4.2.6 Patient BRC010 
Clinical Presentation 
Patient BRC010 is a 52-year-old female, who was diagnosed with breast cancer in 
2012. The patient had a left wide local excision for the removal of a primary tumour 
between 5-10 mm in size in March 2013. Immunohistochemistry analysis revealed 
that all three hormone receptors were present within the tumour tissue (ER+, HER2+ 
and PR+). 
 
Treatment and CT Scans  
A CT scan conducted in September 2012 also showed left axillary lymph node 
enlargement and possible metastatic spread to her cervical vertebrae. However, a 
nuclear medicine (NM) bone scan revealed that these lesions correlated with joint 
degeneration rather than metastatic disease. Several cysts were also present within 
her right ovary however, her liver, spleen, pancreas and adrenal glands all appeared 
normal. The patient was initially treated with non-adjuvant FEC chemotherapy, 
Tamoxifen and trastuzumab. Further, the patient was treated with adjuvant 
radiotherapy at 60 Gy, which concluded in June 2013 along with the Tamoxifen 
treatment. A CT scan in December 2013 showed no swollen lymph nodes, however, 
there was an increase in sclerosis within the patient’s sternum and the previously 
observed lesions within her cervical vertebrae remained unchanged. Metastatic 
disease was diagnosed in March 2016 and an adenocarcinoma removed from the 
pleural space of her lungs which was positive for all three hormone receptors.  The 
patient commenced palliative letrozole treatment at this time. In May 2016 the patient 
underwent a TALC pleurodesis procedure prior to commencing palliative vinorelbine 
chemotherapy and trastuzumab treatment. A further CT scan in June 2016 indicated 
possible new pleural metastatic spread. Multiple sclerotic metastatic deposits were 
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also present within the patient’s thoracic and lumbar vertebrae. The patient finished 
vinorelbine chemotherapy by September 2016 but continued with the trastuzumab 
treatment. Zoledronate was administrated every three months, however, this was 
discontinued after two cycles due to adverse side effects experienced by the patient. 
Palliative Tamoxifen chemotherapy commenced in October 2016 but was stopped in 
May 2017 due to progression of boney metastasis. A subsequent CT scan showed 
degeneration of her bony metastasis with several sclerotic lesions having increased in 
size. The patient then started treatment with palliative trastuzumab and gemcitable. 
By July 2017 radiological imaging showed no metastasis in the patient’s lungs or 
liver and her previously degenerating bony disease appeared stable. 
 
ctDNA Results 
Primary tumour sections stained with H&E are presented in Fig 4.15A, B. Very little 
tumour tissue was able to be extracted from the FFPE tumour blocks for sequencing 
(~15 ng). A novel BRCA1 (Breast Cancer 1) variant (c.349_350delCA, p.His117fs) 
was chosen for ddPCR clinical sample analysis (Table 4.6). In the patient’s FFPE 
tumour DNA, a concentration of 0.183 copies/µL (SD ± 0.234 copies/µL) of mutant 
target was detected. No ctDNA was detectable in the gDNA sample (Fig 4.16).  
 
Seven plasma samples were collected between May and November 2017 and 
analysed. However, no mutant copies were detected in any of the samples (Fig 4.17). 
Therefore, a new mutation needed to be identified and subsequently analysed in the 
plasma, which could not be achieved in this thesis due to time restriction.  
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Figure 4.15 Primary tumour sections stained with H&E for patient BRC010. A) Section at 
20X magnification. B) Section at 40X magnification. Small clusters of concentrated tumour cells 
were observed, however infiltration into the surrounding muscle tissue was also present (black 
arrow). Removal of tumour areas proved difficult and only a small amount of tumour tissue was 
obtained for sequencing.  
 
Figure 4.13 Primary tumour sections stained with H&E for patient BRC010. A) Section at 
20X magnification. B) Section at 40X magnification. Small clusters of concentrated tumour cells 
were observed, however infiltration into the surrounding muscle tissue was also present (black 
arrow). Removal of tumour areas proved difficult and only a small amount of tumour tissue was 





















Figure 4.16 1D amplification for BRCA1 c.349_350delA, p.H117fs in BRC010. 
Samples are presented on the x axis and fluorescence amplitude presented on the y axis. 
Plasma samples are referred to as C1-C8. A manual thresholds were set (pink line) for 
both channel 1 and 2.  A) Mutant droplets are shown in channel 1 (blue). B)Wild type 
droplets are shown in channel 2 (green). Grey droplets below the threshold are 
considered as “rain” and are not included in the final quantification. No mutant droplets 
were detected in any of the FFPE or plasma samples for this patient.  
 
Figure 0.14 Wild type and mutant droplets for BRCA1 H117fs in BRC010. A. 
Mutant target copies in channel 1 (blue) B. Wild type target copies in channel 2 (green). 
No mutant droplets were detected in any of the FFPE or plasma samples for this patient.  
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Figure 4.17 Concentration of BRCA1 c.349_350delA p.H117fs in the plasmas samples of 
patient BRC010. Plasma samples from seven chemotherapy cycles were analysed. No 
ctDNA was detected (0 copies/mL) in any of the plasma samples. Start of treatment is 
indicated by green arrow. A CT scan in July 2017 showed previously observed metastasis in 
the patient’s lung and liver was no longer visible. The patient’s metastatic bony disease was 
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This study identified key variabilities within the general ctDNA analytic pipeline for 
validation and optimisation to suit its use in the New Zealand context. Comparison of 
two commercially available cfDNA blood collection tubes were carried out to 
determine their performance for sample stability. From these results, the Roche Cell 
Free DNA Collection Tubes® where chosen for clinical sample collection. In addition, 
a commercial cfDNA reference standard was used for the validation and optimisation 
of mutation detection (NGS) and quantification techniques (ddPCR). These findings 
suggested that a minimum of 20 ng of input DNA was ideal for targeted sequencing in 
samples with low MAF (≥1%) mutations. The optimisation of in-house designed 
ddPCR assays were highly sensitive, however, their sensitivity was ultimately affected 
by design factors such as position/length of flanking primers, length of probe and the 
nature of the mutation in question. The study findings showed that a background 
threshold for ctDNA response would ideally be 3 mutant copies in the sample. Finally, 
the developed protocol was applied to a pilot study of metastatic breast cancer patients 
for disease surveillance and treatment response in comparison to their routine CT 
scans. For three patients a significant reduction in ctDNA levels was observed by the 
second cycle of chemotherapy. However, for the remaining three, the results obtained 




5.1 Development of the ctDNA Method  
5.1.1 Comparison of Blood Collection Tubes  
The purpose of the study was to determine which of the Streck or Roche cfDNA blood 
collection tubes is preferred for sample collection. Blood samples need to be stable for 
a reasonable length of time, therefore, pre-analytic factors such as the length of period 
between blood draw and sample processing and shipment conditions need to be 
considered for the protection and maintenance of the integrity of cfDNA.  
 
From the results presented in this study, comparisons between Streck Cell Free DNA 
BCTs® and Roche Cell Free DNA Collection Tubes® for sample collection and 
storage at room temperature over a 14-day period showed no statistically significant 
differences. Capillary electrophoresis analysis was used for the fragment size profiling 
of the cfDNA biomarker (~160 bp) and to provide an insight into gDNA 
contamination (>2000 bp). For both tube types, it was observed that gDNA was 
initially present in some volunteers’ sample in both Streck and Roche tubes. This is 
likely due to WBC lysis during phlebotomy sample drawing. The fluorescence level of 
this initial gDNA remained relatively constant across the 14 days and comprised only 
a small proportion of the total sample. This observation indicates that the preservation 
buffer present in both tubes is able to minimise initial gDNA contamination. In 
contrast, samples drawn into the K3EDTA BD Vacutainer® tubes showed a significant 
amount of gDNA increase from day 7 onwards which was similar to results previously 
reported (Fernando et al., 2010, Norton et al., 2013, Kang et al., 2016). These results 
establish that both the Roche and Streck blood collection tubes as suitable for clinical 
sample collection in New Zealand. The proprietary preservation buffers stabilise WBC 
lysis and reduce gDNA contamination for up to 14 days which is an adequate window 
for samples to be transported throughout the country with negligible effect on sample 
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quality. Hence, external factors such as the cost of the tubes and their availability in 
New Zealand were considered to determine which tube was most appropriate for 
future studies. Both tubes cost approximately NZD $12.50 each, the Streck tubes, 
however, have to be couriered from a USA supplier which substantially increases their 
shipping and handling costs. Furthermore, the Streck tubes used in this study were 
made of glass, which has the potential to crack or break under rough handling or high 
centrifugation speeds. In contrast, Roche tubes are readily available through a New 
Zealand supplier and are made of durable polyethylene terephthalate (PET) plastic. 
Therefore after consideration of product price, availability in New Zealand, period of 
preservation stability it was decided to use the Roche Cell Free DNA Collection 
Tubes® for future clinical sample collection.  
 
Two recent publications (published after this study in this thesis was completed) have 
compared the Streck and Roche cell free DNA blood collection tubes (Nikolaev et al., 
2018; Alidousty et al., 2017) along with Qiagen PAXgene tubes and standard 
K3EDTA tubes. These studies observed that a slight increase in gDNA was apparent in 
the samples drawn into the three preservation tubes over a 7 day period. Nevertheless, 
this was significantly lower for the Streck and Roche tube than the gDNA fold 
changes observed in the K3EDTA tubes. Differences regarding the performance of 
sample stability and prevention of WBC lysis between the three preservation tubes 
was not reported. Furthermore, both these studies only demonstrated the preservation 
and stability of samples stored  such tubes for up to 7 days. In contrast, the results 
presented in this thesis made comparisons of Streck and Roche over 14 days, which is 
more suited to the New Zealand context. Both these recent studies indicate that either 
Streck or Roche (and Qiagen) would be suitable for clinical sample collection 
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(Nikolaev et al., 2018; Alidousty et al., 2017), which is similar to the findings in this 
thesis.  
 
Further findings from Nikolaev et al., (2018) did note samples drawn into Roche tubes 
and stored under  fluctuating temperatures  (22ºC-30ºC) had detectable gDNA levels 
from day 5 onwards, whereas no gDNA was detected in either Streck or PAXgene 
tubes under the same regime.  The findings in this thesis only measured sample 
stability at room temperature. Roche indicate that these samples drawn in these tubes 
are stable during fluctuations in temperature ranging from 4-37ºC (Roche, 2018), thus 
further validation maybe prudent to confirm the observed gDNA increase under 
fluctuation temperature observed by Nikolaev et al. (2018).  
 
5.1.2 Determining the Minimum DNA Input for Targeted NGS in Samples 
with Low Mutant Allele Frequency  
The advancement of DNA sequencing technologies provides a highly sensitive 
multiplex method for routine variant detection (Buermans and den Dunnen, 2014). 
WGS and WES provide a comprehensive view of the DNA either at a whole genome 
or exome level. However both these procedures are costly and in certain scenarios 
only a low coverage is feasible, thereby reducing their sensitivity for the detection of 
rare somatic mutations (Meienberg et al., 2016).  
The use of targeted gene panels has become more prevalent in cancer genome studies 
as their application has been shown to reduce associated costs, duration of sequencing 
and complexity of bio-informatics analysis (Horak, Fröhling, and Glimm, 2016). The 
optimisation of targeted sequencing protocols using commercially available library 
preparation and target enrichment kits for mutation detection has been utilised in 
previous ctDNA studies (Kaisaki et al., 2016 Malapelle et al., 2016; Shu et al., 2017) . 
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Standardisation and the subsequent development of guidelines for such procedures is 
important for future clinical adoption. In particular, sequencing retrospective FFPE 
tumour samples for somatic mutation detection is an efficient method for the 
identification of genetic alterations which may cause resistance to treatment and 
metastatic dissemination.  
A significant limitation of sequencing retrospective FFPE tumour samples for somatic 
mutation detection include the amount of DNA available for sequencing which is 
affected by several factors such as size of the tumour, age of tumour block and tissue 
integrity (Do and Dobrovic, 2015). Arreaza et al. (2016) described the optimal DNA 
input as the lowest amount of sample DNA for the generation of highly biologically 
complex libraries. In theory, all of the available genome copies within a sample would 
be utilised in library preparation. However depending on each commercial kit’s 
efficiency, it is possible that only some of the sample is utilised. Therefore the amount 
of DNA in the starting sample significantly correlates with the final read depth of the 
sample and subsequently the number of variants detected in the final output (Arreaza 
et al., 2016).  
Chung et al. (2016) studied the optimisation of targeted sequencing protocol for FFPE 
tumour DNA from lung cancer patients. Chung and colleagues (2016) compared 
several commercially available library preparation kits to investigate the correlation of 
sample DNA input and mean target coverage. From their findings they were able to 
achieve on average a 300X coverage for samples as little as 6 ng with a MAF of 15%. 
Despite the success of these findings, the use of FFPE tumour DNA in their study may 
be a limitation for its application in future studies. The use of reference standards may 
provide a more standardised methodology.  
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One aim of the research described in this thesis was to utilise cell line-derived cfDNA 
reference standards consisting of eight known somatic mutations to identify an optimal 
DNA input amount for samples at 1% allele frequency. Three different input amounts 
(20 ng, 5 ng and 1 ng) were compared for mean target coverage and the number of 
variants identified. Comparison were also made against a pooled healthy gDNA 
sample (20 ng) as a baseline reference for number of detected variants in healthy 
individuals. The ThruPlex TagSeq kit was used for library preparation and the Agilent 
SureSelect XT kit for target enrichment. A custom gene panel consisting of 578 cancer 
variants from Roche’s Comprehensive Cancer Design panel was used for variant 
calling. A decreasing trend of DNA input amount to mean target coverage was 
observed for the reference standard samples. All samples had a similar number of 
Single  Nucleotide Variant (SNV) which is attributed to de novo variants within the 
germline (Milholland et al., 2017). Comparison of the number of indels 
(insertion/deletions) identified the 20 ng sample with the highest number of indel 
mutations compared to the 5 ng and 1 ng samples. Upon further comparisons, the 
number of “variants by consequence” (frameshift, non-synonymous, stop-gained and 
stop-lost) were very similar between the 20 ng and 5 ng sample despite a difference of 
40x target coverage. However, 5 ng of sample may be inadequate to achieve a decent 
amount of target coverage for FFPE compromised DNA samples.  
 
The results of this study demonstrate the feasibility of utilising a target gene panel for 
sequencing samples with a low MAF. As the 20 ng of DNA produced the highest 
coverage for variant detection, it could be considered as a minimum amount of DNA 
for future clinical sample sequencing. Nevertheless it is important to note that in due 
to patient variability it is not always feasible to obtain this amount of DNA for input, 
however for this study 20 ng was utilised as a threshold for FFPE tumour DNA 
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extraction in the clinical samples. Hence to increase both the sensitivity and read depth 
for clinical sample sequencing, a smaller commercial breast cancer gene panel  was 
implemented in the pilot study.  
 
5.1.3 Optimisation of in-house ddPCR Assays  
The detection sensitivity of the NRAS and PIK3CA assay was 0.03% and 0.49% 
respectively. The NRAS Q61K assay had a sensitivity of 3 mutant copies at three in 10, 
000 wildtype background copies. These results were significant for all three spike-in 
samples as there was no overlap of the 95% confidence intervals with that of the 
negative control gDNA sample (BioRad, 2017). Nonetheless, one droplet containing 
both wild-type and mutant target was detected in one NTC well. It is possible that this 
was due to cross-contamination, but it is also likely that it was due to non-specific 
amplification (Jones et al., 2014).  
 
Despite using the same gDNA concentration used in the PIK3CA E545K assay, 
approximately only 5000 total (wild type and mutant) copies were detected. 
Significant results were only observed for the 5% and 1% reference standard samples. 
The results from the 0.1% sample had an overlap of error bars with those of the gDNA 
and is likely to be false positive result (BioRad, 2017). From these findings, it was 
decided to adopt a threshold of 3 mutant copies for ctDNA analysis in clinical 
samples. It was also decided that samples with less than 3 mutant copies will be 
deemed as inconclusive requiring further analysis or comparisons with different 
mutations. 
 
The differences observed for the detection limits between the two assays is gene 
specific and may be affected by assay design. Factors that influence assay efficiency 
include primer/probe design, probe cross-reactivity and amplicon size (BioRad, 2017). 
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All ddPCR assay in this study were manually designed based on BioRad RED assay 
recommendations. While every effort was taken to design highly efficient assays, sub-
optimal primers and probes may be discovered empirically as the study progresses. A 
potential solution to this problem would be to purchase commercial wet-lab validated 
ddPCR assays from BioRad directly. However, these assays are costly and only 
consist of enough reagent to run 200X reactions (compared to IDT’s 1000X). 
Furthermore, commercial assays are currently not available for unknown rare 
mutations, thereby limiting the turnaround time for clinical application.  
 
From these results it was apparent that assay design plays an essential role in the 
detection sensitivity of mutations in question. Previous publications have described 
both NRAS Q61K and PIK3CA E545K in-ddPCR assays and upon comparison differ 
in primer flanking positions, probe length and amplicon size (Grey et al., 2014; Cheng 
et al., 2015; Frenel et al., 2015; Kim et al., 2015; Christensen et al., 2017). The NRAS 
Q61K is a common mutation in melanoma patients (Johnson and Puzanov, 2015). 
Cheng et al. (2015) designed an in-house ddPCR assay for this mutation to detect 
disease progression in the ctDNA of melanoma patients. From their findings, Cheng 
and colleagues (2015) identified a background mutant threshold of 3 copies/mL for 
their NRAS assay. Analysis of patient ctDNA at or above this threshold for this 
mutation was considered as “elevated” (Cheng et al., 2015). The use of the 
commercially available BioRad assay has been used in several studies. Grey et al. 
2014 utilised this assay for the detection of the NRAS Q61K mutation in a cohort of 
metastatic melanoma patients. From their methods, an optimal annealing temperature 
of 55°C was noted for its PCR amplification. This is comparably lower than the 




The PIK3CA E545K mutation plays a significant role in the progression of breast 
cancers and several studies have published in-house ddPCR assays (Frenel et al., 
2015; Christensen et al., 2017). The assay in this study was compared to an in-house 
assay designed by Frenel et al. (2015). Different forward and reverse primers were 
designed and implemented by Frenel et al. (2015) while the probes between the two 
studies differed only by a few bp upstream and downstream of the target location. The 
annealing/extension temperature used in this thesis was also comparatively lower 
(60.1ºC) than that previously published assay (63ºC) (Frenal et al., 2015). Frenel and 
colleagues demonstrated that their assay was accurately able to detect the PIK3CA 
E545K mutation within plasma samples in patients at allele frequencies of 1% (3 
patients) and 5% (1 patient), which was comparable to the results obtained in this 
thesis. An in-house ddPCR assay for this mutation was also designed by Christensen et 
al. (2017). Comparisons with their assay showed different primers and a slightly 
longer mutant probe in their study.  A further study utilising BioRad ddPCR assays for 
the E545K mutation identified an annealing/extension temperature of 55.8ºC (Kim et 




5.1.4 Comparison of ddPCR Quantification Software  
 The algorithms for QuantaSoft Pro ™ droplet classification and the associated 95% 
confidence intervals are proprietary. Thus, a comparison against the freely available 
“twoddPCR” R package (Chiu et al., 2017) for the analysis of the raw amplitude data 
was carried out to determine similarities and differences between the two types of 
analyses. The concentration (copies/uL) for the mutation and wild-type targets for both 
assays were relatively similar between twoddPCR and those calculated by QuantaSoft 
Pro™. Statistical significance for the twoddPCR results was not available as the R 
package does not calculate Poisson error or total error. Correspondence with the lead 
author of the package confirmed that the 95% confidence intervals (CI) were 
externally calculated, however, they were not comparable with the QuantaSoft Pro™ 
values. Biostatistician, Associate Professor Mik Black advised using the “binom.test” 
function in R to calculate the confidence intervals (see section 2.3.1). A comparison of 
binom_test 95% CIs were significantly lower than the ones calculated by the 
commercial software. For future clinical samples, the twoddPCR R package may 
prove useful for identifying ambiguous droplets and re-classifying them based upon 
the “Mahalanobis distance-based approach.” However, further development of 
comparable statistical inference is required for clinical sample analysis. 
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5.2 Clinical application of ctDNA analysis in metastatic breast cancer 
patients. 
The increasing number of cancer patients poses an economic burden to New Zealand’s 
health care sector. Current clinical tools used for diagnosis and surveillance include 
radiological imaging and invasive surgical biopsies. Metastatic breast cancer within 
New Zealand makes up a significant proportion of total cancer patients. The 
identification of stable or progressive disease via radiological imaging plays an 
important role in the type of treatment administered (Alunni-Fabbroni et al., 2014).  
 
This study applied the previously developed ctDNA methodology to determine 
metastatic breast cancer patient’s response to treatment in a shorter period than current 
clinical practices. Eighteen breast cancer patients were recruited in this study, 
however, adequate plasma samples and FFPE primary tumour blocks were only 
obtained from six patients within the timeframe the research was carried for this thesis. 
Tumour DNA was extracted from each patient’s primary tumour block and sequenced 
using targeted NGS with a specific breast cancer gene panel. A pathogenic variant was 
chosen for each patient and an in-house ddPCR assay designed. Mutations were then 
quantified in the patients’ plasma samples obtained over their respective course of 
treatment.  
 
The results from this study showed a significant reduction in ctDNA levels for three 
breast cancer cases within the first two cycles of chemotherapy (BRC001, BRC006 
and BRC007). However, ctDNA analysis was inconclusive for the remaining three 
patients due to insufficient or lack of detectable ctDNA (> 3 mutant copies/mL) 
(BRC005 and BRC010) and poor ddPCR assay design (BRC009) The variants chosen 
for ddPCR follow-up were based on their predicted pathogenicity and potential to be 
present within the metastatic lesions.  
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5.2.1 Metastatic Cases with Positive ctDNA Response to Treatment 
BRC001 
Patient BRC001 primary tumour was classified as HER2 enriched. These types of 
tumours typically involve anti-HER2 treatments especially in metastatic cases such as 
trastuzumab; a recombinant monoclonal antibody that binds to the HER2 receptor’s 
extracellular domain IV (Slamon et al., 2001; Capelan et al., 2013). A novel TP53 
(p.V97fs, c.288_289A) variant was identified from sequencing the patient’s primary 
tumour DNA. Currently there is no relevant clinical information available for this 
specific variant, thus it is difficult to draw conclusions on its function in relation to 
breast cancer. However, studies have identified that TP53 frameshift indels are highly 
prevalent in HER2 enriched breast cancers and contribute to overall disease 
progression. Furthermore, TP53 status is a potential prognostic marker in such HER2+ 
disease and variants are typically present at both primary and metastatic sites (Darb-
Estafani et al., 2016; Yates et al., 2017).  
 
Patient BRC001 had an positive response to treatment within the first two cycles. The 
significant decrease in tumour burden was confirmed by a CT scan ~5 weeks post 
ctDNA observation. This is a significant result as a novel TP53 unconfirmed potential 
driver mutation in relation to HER-enriched metastatic breast cancer was identified in 
this thesis. Furthermore, ctDNA analysis of this variant detected a response to 
treatment before it was detected by routine surveillance. Nevertheless, further 
characterisation studies in relation to this mutation will need to be carried to determine 






Patient BRC006 is an ER+ breast cancer patient with metastatic disease in her gastric 
pylorus, bone and liver. A suspicious metastatic mass was detected in the patient’s 
most recent CT scan, however this observation has yet to be confirmed. A novel 
CDH1(p.V391fs, c. 1171delG) was detected in the patient’s primary tumour. Invasive 
lobular breast cancers typically lack the CDH1 protein E-cadherin, due to frameshift 
indels and nonsense mutations (Berx and Roy, 2001). Previous studies have 
characterised several CDH1 frame-shift indels specifically within breast cancer. 
Gellert et al. (2016) identified CDH1 in the top three most frequently mutated genes in 
a cohort of ER+ breast cancer patients. Furthermore, mutational analysis revealed, 
frameshift variants were predominant in CDH1, whereas other significant genes such 
as TP53 and PIK3CA contained missense mutations. CDH1 variants in lobular breast 
cancer have also been associated with metastatic spread to the GI tract, bone and less 
commonly the lungs (Bose, 2013). Further verification of the nature of this variant 
through gene characterisation studies is required, however from this study, it was 
observed to be a useful marker of the patient’s treatment response.  
 
BRC007  
Patient BRC007’s cancer was classified as HER2 enriched with metastatic mass in her 
lungs and metastatic bony disease. Sequencing of the patient’s primary tumour 
identified a novel KMT2C variant (p.Gly838Ser, c.2512G>A). KMT2C belongs to a 
family of histone methyltransferases whose roles include transcription regulation. 
Mouse and drosophila models have provided evidence that KMT2C functions normally 
as a tumour suppressor as loss of function studies have resulted in growth advantage in 
comparison to the wild type version (Rao and Dou, 2015). However, from our study, it 
was observed that this particular variant was germline and produced significant high 
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mutant copies in the pooled healthy gDNA. The PIK3CA (p.E545K c.1633G>A) was 
also identified in this patient’s sample. As this particular variant has a high pathogenic 
relationship with metastatic breast cancer and its ddPCR assay was readily available, it 
was decided to carry out ctDNA plasma analysis using this variant. Many studies have 
characterised PIK3CA E545K as a ‘hot-spot’ mutation and its potential as a prognostic 
variant for treatment response in hormone receptor positive patients (Pang et al., 
2014). The variant’s resistance to specific breast cancer treatments such as paclitaxel 
and trastuzumab has been successfully demonstrated in cell culture models (Isakoff et 
al., 2005; Berns et al., 2007). Furthermore, studies in HER2+ cohorts studied showed 
patients with this particular variant have a poor response to neoadjuvant anti-HER2 
targeted therapies (Majewski et al., 2015).  
 
Patient BRC007 showed a positive response to treatment, observed from the sudden 
decrease in ctDNA levels from cycle 2 onwards. A decrease in metastatic disease was 
also observed in a mid-treatment measured by CT scans,  perhaps explaining why no 
ctDNA was detected post three chemotherapy cycles. The clinical notes available for 
this patient indicated that the patient’s metastatic bone lesions had become scleoritic 
(abnormal hardening of bone tissue) which has previously been linked to a positive 
response to therapy (Ciray et al., 2000).   
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5.2.2 Metastatic cases with inconclusive ctDNA results  
BRC005 
Patient BRC005’s primary tumour was characterised as TNBC due to the lack of 
hormone receptors and HER2 expression with metastatic disease in her lungs. A 
biopsy of the mass within her lung revealed the same triple negative characteristics as 
the primary tumour. The TP53 (p.Y220, c.659A>G) variant was identified in the 
patient’s primary tumour and is one of the most prevalent cancer mutations, 
accounting for ~75,000 new cancer cases every year world-wide (Joerger and Fersht, 
2007). Characterisation studies have shown this variant to be involved in the 
destabilisation of the TP53 protein and down-regulation of apoptosis (Rauf et al., 
2013; Meißner et al., 2017). The germline presence of this mutation has also been 
linked with individuals diagnosed Li-Fraumeni syndrome, an inherited disorder which 
predisposes to early onset cancer (Xu et al., 2014). 
 
The highly pathogenic nature of this variant makes it an ideal candidate for ctDNA 
analysis (Song et al., 2015). In this study however, no significant amount of the TP53 
ctDNA variant was detected in the patient’s plasma sample. Slight fluctuations were 
observed in samples, however these were all below the minimum threshold of 3 
mutant copies/mL. This was a surprising result due to the highly pathogenic nature of 
the variant and its previous description as a significant cancer driver (Song et al., 
2015). It is possible that the lack of variant in the plasma observed in the current study 
is due to successful previous treatment.  A possible reason for the lack of detectable 
variant is its absence within the secondary metastatic tumours. This scenario has been 
previously observed in TNBC cases. Nevin et al. (2011) identified metastatic tumour 
cells as genetically distinct from the primary tumour in TNBC cases. Sequencing the 
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tumour DNA from the secondary mass is a possible solution for identifying metastatic 
driver mutations. 
 
In contrast, recent publications have successfully shown ctDNA analysis in metastatic 
TNBC patients for treatment response. Madic et al. (2014) examined TP53 mutations 
within the ctDNA of TNBC metastatic cases and found that these types of tumours 
may produce lower ctDNA concentrations and that the mechanism of ctDNA release 
may differ distinctly between patients, (Heidary et al. 2014). A different method of 
ctDNA analysis was recently published by Stover et al. (2018) for the quantification of 
the tumour fraction of the ctDNA in a cohort of 164 TNBC patients using WGS. From 
their findings, they determined that patients with ctDNA fractions greater than 10% 
correlated to poor survival and gain and loss of copy numbers within specific genes 
with observed higher frequencies in metastatic cases compared with primary tumour 
TNBC (Bujak and Dawson, 2018). Furthermore, the breast cancer panel used for 
targeting sequencing in this study, potentially limits the scope of mutations detected 
within TNBC primary tumours. Thus the identification of novel variants not 
previously linked to breast cancer, but which may be driver mutations in specific 
metastatic sites, are unlikely to be identified using existing pre-selected gene panels as 





BARD1 forms a heterodimer protein complex with BRCA1 (Baer & Ludwig, 2002). 
Specific missense mutations within the BARD1 gene have been shown to induce 
cancer progression by disrupting the tumour suppressor function of BRCA1 
(Klonowska et al., 2014). Germline mutations within the BARD1 gene have been 
linked to hereditary breast and ovarian cancer cases (Thai et al., 1998).  Unfortunately, 
ctDNA analysis for the presence of the BARD1 variant identified in this patient was 
unable to be carried out as the in-house ddPCR designed assay resulted in cross-
reactivity between wild type and mutant probes. Reasons for this cross reactivity are 
unclear, however discussion with Dr. Sol Green from BioRad suggest inefficient probe 
design and/or variant position as possible causal factors. Due to time constraints, 
follow up with an alternative variant for ctDNA analysis was beyond the scope of the 
current research would be implemented in future research.  
 
BRC010 
The BRCA1 gene encodes a protein that acts as a E3 ubiquitin ligase upon dimerisation 
with BARD1. This protein complex has a significant tumour suppressor role as it is 
actively involved in DNA repair (Silver & Livingston, 2012). From the ctDNA 
analysis of patient BRC010, a novel BRCA1 variant (H17fs, c.349_350delCA) was 
identified and a ddPCR assay designed. However subsequent plasma sample analysis 
revealed that this variant was undetectable in any of the analysed samples. From the 
clinical notes provided for this patient it was identified that the tumour burden was 
relatively small (5-10 mm). Furthermore, very little tumour DNA was available for 
extraction from the primary tumour sections and subsequent sequencing depth would 
have been affected. CT scans identified stable metastatic bone disease and 
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significantly reduced metastatic disease in the patient’s liver. Therefore it is likely that 
the tumour burden was too low for detection via ctDNA analysis.  
 
5.2.3 Summary  
The small sample size in the clinical study was a limitation of this study. Despite this, 
a wide variety of breast cancer subtypes were observed. Several factors are thought to 
contribute to the low levels of ctDNA observed in two of the patients. Firstly, the sites 
of metastatic disease could potentially  have had very low ctDNA levels released into 
the circulation such as bony disease within the ribs and spine. Furthermore, ctDNA 
analysis for very small tumours (such as that observed in BRC010) may lack the 
sensitivity to detect very low mutant copy numbers, which has implications for 
monitoring patient relapse. Finally, the loss of the driver mutant over the patients 
course of disease or clonal evolution can impact on surveillance observations. 
Therefore multiple variants need to analysed to confirm such findings.  
 
In effort to address these issues, alteration to the protocol may include the use of laser 
capture microdissection for removal of purely tumour cells from surrounding tissue 
and protein in FFPE samples (Braakman et al., 2011). The use of a larger gene panel 
in targeted sequencing  may enable the detection of a wider range of potential 
pathogenic mutations. Finally, sequencing the immediate plasma sample prior to a 
new treatment will allow the identification of driver mutations currently present within 
the circulation, allowing a more comprehensive characterisation of the patients 
metastatic lesions. This last procedure is currently being carried out in the research 
laboratory for all six patients mentioned in this thesis .  
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5.3 Conclusions and Future Directions  
This study contributed significantly to develop the ctDNA methodological pipeline for 
its use as a clinical surveillance tool for cancer here in New Zealand. From these 
findings a cost effective and easily available blood collection tube for sample 
collection across New Zealand was identified. This research has also identified 
thresholds for DNA input for targeted sequencing and the number of mutant copies 
required (threshold) to indicate a response to treatment using ctDNA analysis. 
 
Some success was also observed in a small pilot study for the clinical application of 
ctDNA analysis in monitoring tumour burden and treatment response in metastatic 
breast cancer. However, factors such as intra-tumour heterogeneity, and minute 
tumour size impacted on sensitivity and output for some samples. Further development 
and optimisation, specific to metastatic breast cancer will aid in increasing the 
detection sensitivity in such patients.   
 
Future research requires the development of a quality control system within NGS and 
ddPCR for routine clinical use. In regard to the pilot breast cancer study further 
analysis in more patients may provide further insight into the inter and intra tumour 
heterogeneity of breast cancer. Recommended future research includes 
1. sequencing the first plasma sample to compare the presence of driver 
mutations within the plasma to those within the primary tumour 
2. development of a custom breast cancer NGS targeted gene panel consisting of 
a wider variety of cancer driver genes to facilitate a means of identifying 




The findings presented in this study provides a foundation for future development of 
ctDNA analysis within New Zealand. The utilisation of a blood sample for cancer 
detection may enable the routine surveillance of patients who may have difficulty 
accessing specialist health care services. The ultimate shift of cancer management out 
of secondary hospital care and into our communities will help reduce the burden 
cancer has on our society and enable to achieve the New Zealand Health Strategy of 
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Appendix A  
Concentration of Total DNA in cfDNA Collection Tubes 
 
Table A1. Concentration of total DNA in plasma of healthy volunteers preserved in 
Streck Cell Free DNA BCTs® over 14 days (ng/mL)  
 
 
Subjects Day 0 Day 4 Day 7 Day 10 Day 14
S01 2.02 5.05 6.28 11.64 4.11
S02 4.70 5.03 7.95 11.55 4.66
S03 5.67 4.81 7.33 9.19 7.04
S04 4.89 6.00 9.98 8.61 2.35
S05 4.94 7.03 7.23 6.02 7.04
S06 7.53 6.50 6.62 6.30 5.49
S07 7.01 4.80 5.92 5.43 7.49
S08 2.63 3.59 3.52 5.60 5.14
S09 3.68 5.98 7.99 5.93 5.52
S10 3.47 5.21 6.37 5.64 7.14
S11 7.53 6.00 7.24 8.58 6.62
S12 2.63 4.69 6.62 3.07 3.72
S13 3.18 4.33 7.27 4.27 4.64
S14 2.60 5.81 5.79 3.45 4.50
S15 3.56 6.74 5.21 4.22 5.32
S16 13.21 6.00 11.99 10.24 15.05
S17 9.54 6.00 8.12 3.29 6.31
S18 11.55 8.71 9.80 6.92 8.15
S19 5.44 6.40 5.66 6.03 13.65
S20 8.20 11.38 7.94 12.51 8.11
Mean 5.70 6.00 7.24 6.92 6.60
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Table A2. Concentration of total DNA in plasma of healthy volunteers preserved in Roche 
Cell Free DNA Collection Tubes® over 14 days (ng/mL) 
 
  
Subjects Day 0 Day 4 Day 7 Day 10 Day 14 
S01 2.39 4.38 6.46 4.27 3.73
S02 3.26 3.31 5.86 10.59 6.83
S03 2.96 4.43 6.45 5.76 4.60
S04 4.15 8.93 6.05 5.88 7.56
S05 3.54 10.59 6.63 6.90 5.23
S06 5.88 6.74 6.81 5.93 6.67
S07 3.00 5.57 7.78 6.14 7.50
S08 2.94 3.27 3.55 5.30 6.36
S09 3.00 5.67 5.04 6.88 7.95
S10 3.76 4.79 4.71 6.32 6.73
S11 5.94 6.22 5.71 9.28 8.12
S12 2.08 4.04 4.85 4.10 4.70
S13 3.04 6.22 6.86 6.08 6.02
S14 2.84 4.22 4.48 5.80 3.78
S15 3.12 4.83 6.35 5.10 6.83
S16 10.41 10.76 11.20 10.15 11.64
S17 11.11 6.39 9.01 7.10 7.89
S18 9.54 9.45 8.84 8.25 9.36
S19 8.07 6.42 7.59 6.01 8.31
S20 8.16 8.16 12.95 11.03 10.41
Mean 4.96 6.22 6.86 6.84 7.01
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Appendix B  
Temperature Gradient Droplet Graphs  
 
 
Figure B.1 Temperature gradient ddPCR run for PIK3CA E545K variant. Optimal 
temperature was 60.1°C. Channel 1 (blue) consists of the FAM fluorophore while channel 2 
(green) consists of the HEX fluorophore.  
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Figure B.2 Temperature gradient ddPCR run for NRAS Q61K. Optimal temperature was 
61.4°C. Channel 1 (blue) consists of the FAM fluorophore while channel 2 (green) consists of 
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Figure B.3. BioRad recommended setting for ddPCR RED assay design using Primer3Plus.  
Gene Variant Chromosome 
EGFR L858R 7p12
EGFR ΔE746 - A750 7p12
EGFR T790M 7p12







Table B.3 Variants by Consequence from Illumina Enrichment Report for 20 ng of cfDNA 
reference standard at 1 % MAF 
 
 
Table B.4 Variants by Consequence from Illumina Enrichment Report for 5 ng of cfDNA 






Temperature Gradient ddPCR Assays for Clinical Samples  
 
 
Figure C.1 Temperature gradient ddPCR run for BRC001 TP51 TP53 V95fs. Optimal 
temperature was 58.2ºC. Channel 1 (blue) consists of the FAM fluorophore while channel 2 
(green) consists of the HEX fluorophore.   
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Figure C.2 Temperature gradient ddPCR run for BRC005 TP53 Y220C. Optimal temperature 
was 56ºC. Channel 1 (blue) consists of the FAM fluorophore while channel 2 (green) consists 
of the HEX fluorophore. 
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Figure C.3. Temperature gradient ddPCR run for BRC006 CDH1 V391fs. Optimal 
temperature was 58.2°C. Channel 1 (blue) consists of the FAM fluorophore while channel 2 
(green) consists of the HEX fluorophore. 
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Figure C.4. Temperature gradient ddPCR run for BRC007 KMT2C G838S. Variant was a 
germline heterozygous mutation and thus not an appropriate target for RED ctDNA analysis. 
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Figure C.5. Temperature Gradient for BRC009 BARD1 R658C. Cross reactivity with the wild 
type and mutant probes. 
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Figure C.6. Temperature gradient for BRC010 BRCA1 H117fs. Very little patient tumour 
DNA was available, decided on an optimal temperature of 52.7°C. Channel 1 (blue) consists of 
the FAM fluorophore while channel 2 (green) consists of the HEX fluorophore. 
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Table C1. Qubit Reads for BRC001  
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Table C4. Qubit Reads for BRC007 
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Plasma Sample Concentration(ng/mL) 
1 455
2 467
3 368.8
4 379
5 215
6 202.7
7 240.29
8 530
9 160.7
10 288.9
11 317.45
BRC010
Plasma Sample Concentration(ng/mL)
1 20.2
2 22.54
3 29.2
4 24.12
5 67.16
6 25.68
7 17.8
